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Abstract
Calcium silicate hydrate (CSH), a new type of bioceramics, has gained significant attention
in hard tissue restoration because of their impressive role in the stimulation of osteoblast
proliferation and differentiation in vitro. The further development of mesoporous
bioceramics opens up new opportunities for drug delivery in hard tissue therapies. In this
thesis, interaction mechanisms of drug molecules with CSH of different morphologies and
CSH/polymer composites, imaging of drug distributions in CSH carriers in nanoscale, and
the biomineralization mechanisms of CSH in vitro during drug release are extensively
investigated using X-ray absorption near edge structure (XANES) and scanning transmission
X-ray microscopy (STXM).
The interactions between different drug molecules and CSH with different morphologies are
investigated using XANES. It is found that the morphology and the presence of hydrates of
drug carriers influence the drug loading capacities (DLCs). CSH provides active linkage sites
(Ca-OH and Si-OH groups) for the acidic functional groups of drug molecules via
electrostatic interactions. Besides, it is also found that the stoichiometric ratio of Ca2+ ions of
CSH carriers to the functional groups of drug molecules will significantly influence the
DLCs. The mapping of an individual CSH microsphere, which was synthesized by a
sonochemical method, before and after the loading of ibuprofen (IBU) is recorded by STXM.
This STXM-XANES study illustrates the integrity and the homogenously distribution of drug
molecules in these drug carriers.
The biomineralization of the drug carrier, CSH microspheres upon IBU release, are
monitored with XANES and STXM. The biomineralization mechanisms for CSH
microspheres loaded with IBU in the SBF solution, which were still controversial before,
emerge via STXM mapping, spectral comparisons and fitting analysis.
Finally, CSH/polymer composites were synthesized using a controlled precipitation reaction
between calcium salt and silicate salt, followed by the addition of various polymer solutions
ii

at room temperature. The interactions between different polymers and CSH, the interactions
between drug molecule IBU and these polymer composites have been extensively studied by
XANES. We find that the polymers alter the structure of CSH to various degrees, and that
this behaviour further influences the DLCs and drug release kinetics.

Keywords
biomineralization in vitro, calcium silicate hydrate, calcium silicate hydrate/polymer
composites, drug-carrier interactions, scanning transmission X-ray microscopy, X-ray
absorption near edge structure
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Chapter 1
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Introduction

1.1 Biomaterials
1.1.1

General Background

Bone not only is a hard form of supportive organ, but also keeps the essential inorganic
elements for human beings, particularly calcium and phosphate. Bone consists of
minerals (mainly hydroxyapatite, HAp), collagen, water, noncollagenous proteins, lipids,
vascular elements and cells [1, 2]. Besides HAp, a few trace elements for different
metabolic functions are enriched in minerals, such as carbonate, citrate, sodium, fluoride
etc. Organic phases provide tensile strength and flexibility while the minerals which are
embedded onto collagens to strengthen the bone. Hence, a healthy skeletal system is
essential to overall health and quality of human life.
However, according to the report of the U.S. Department of Health and Human Services
(2004), annually, 1.5 million Americans suffered wrist, spine, and hip fractures which are
due to bone diseases [3]. One of the most common bone diseases is osteoporosis (low
bone mass), leading to the deterioration of bone structure [4]. Other bone diseases include
Paget’s disease (skeletal deformities and fractures) and osteogenesis imperfect (inherited
bone disorder). Under these circumstances, surgical treatment to repair or replace
damaged bone is inevitable. Traditionally, autograft (graft is implanted from the same
patient) has been used for a long time, but the source of autograft is limited; another ways
are allograft or xenograft (from another individual or animals), nevertheless, they
suffered from pathogen transfer and graft rejection [2]. As a result, people tried to utilize
synthetic materials which have the same ability to repair or replace the defective bone
system. These kinds of synthetic or biologically derived materials are called biomaterials.
The first use of biomaterials for hard tissue treatment can be dated back to ancient Egypt;
they used elephant’s tusks to replace bone or missing teeth [5]. However, the practical
use of biomaterials for hard-tissue treatment was unsuccessful until the development of
aseptic surgical technique in 1860s, because most of previous failures were due to
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infection [6]. The development of modern biomaterials for bone treatment started from
the 1960s and 1970s, when the first generation of biomaterials called prostheses were
invented. Since then, there were more than 50 implanted devices in clinical used made
from 40 different materials, however, none of them was bioactive or bioresorbable [7].
By 1984, a second generation of biomaterials which was to be either bioactive or
bioresorbable had been engineered [8]. By the mid-1980s, bioactive materials including
various bioactive glasses, ceramics and composites had been applied in clinical use. The
third generation of biomaterials has made further progresses; they are designed to
stimulate specific cellular responses at the molecular level [9]; bioactive materials are
being made resorbable while bioresorbable polymers are being designed to be bioactive.
Currently, biomaterials which should be biocompatible, nontoxic, sterilisable etc., have
improved the quality of human life year after year. In 2000, the biomaterials market was
valued around $30 billion USD, the demand for biomaterials to repair or replace bone
tissue continued to increase during the last decade [2, 10].
So far, biomaterials can be classified into metallic biomaterials, ceramic biomaterials,
polymeric biomaterials and composite biomaterials. Normally, metals and ceramics are
applied in hard tissues treatment, while polymers are used in soft tissue applications.
Since the studies in this thesis are focused on the biomaterials applied in hard-tissue
engineering, metallic, ceramic biomaterials and composite biomaterials will be
introduced below.

1.1.2

Metallic Biomaterials

Since early 1900s, metals have been used as biomaterials because of their excellent
electrical and thermal conductivity, as well as mechanical properties. They served as
substitutes such as hip or knee joints for fracture healing implants. Until now, stainless
steels [11], cobalt-chromium alloys [12, 13], titanium and Ti-based alloys [14, 15] have
been used as biomaterials. The major advantages of these metals and alloys are their
biocompatibility, impressive mechanical properties and reasonable cost. Ti and its alloys
gain more preferences right now since they are lighter and have superior corrosion
resistance. In addition, some noble metals (Au, Pt, Pd. etc.) and amalgam have been also
utilized as biomaterials to replace tooth roots for dental applications [16].
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Although these metallic biomaterials have been applied in hard-tissue treatment
successfully, they are still lack of mechanical compatibility with natural bone to some
extent. Moreover, metals do not have the ability to interact with human tissue, leading to
the limited integration with the bone. To overcome this issue, hydroxyapatite coated
metallic implants are introduced in most of treatments [17].

1.1.3

Ceramics Biomaterials

Ceramics in the form of pottery or concrete have been used by humans for thousands of
years. People did not realize that ceramics could be also used to bone tissues
augmentation and repair until 1920 [18]. Thus, these ceramics used in hard-tissue
applications are categorized as ceramic biomaterials or bioceramics. Around 60% of the
bone graft substitutes on the market are related to bioceramics [10]. They can also be
classified as non-absorbable (relative inert), bioactive or surface reactive [19] and
biodegradable or bioresorbable [20].
Relatively inert bioceramics maintain their physical and mechanical properties while they
are implanted in the host. Aluminium oxides and zirconia ceramics are the typical
examples of these bioceramics [21, 22]. Based on their characteristics, they are used as
structural-support implants. Bioactive or surface reactive bioceramics such as bioglass
[23] are very important for the application in the coating of metal prostheses because of
their strong bonding with adjacent tissue once implanted in the host. Calcium phosphate
(CaP) based bioceramics are another representative examples of bioceramics. They have
a long history of bone repair since 1920 [24], some of them like β-tricalcium phosphates
are biodegradable materials, nevertheless, their degradation rate is not satisfactory [25].
Moreover, although CaP bioceramics possess the ability of bone growth on the materials
surface, they lack the ability of recruitment of immature cells and the stimulation of these
cells to develop into pre-osteoblasts. Another common disadvantages of all bioceramics
are that they are brittle, lower toughness and not resilient.

1.1.4

Composite Biomaterials

Currently, the development of composite biomaterials (ceramics/polymer) is attractive
because the advantages of two or more kinds of materials can be combined and the
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shortcomings of a single phase biomaterial, such as poor mechanical property for
bioceramics and poor bioactivity of polymeric biomaterials, can be overcome
simultaneously [26]. For example, Bonfield et al. first introduced the bone analog
concept using HAp particulate-reinforced high-density polyethylene (HDPE) composites
in 1981 [27]. Until now, nanocomposite biomaterials have been applied into various
biomedical applications as a new and versatile class of biomaterials for hard tissue repair
and regeneration. Poly(lactic-co-glycolic acid) (PLGA), poly-L-lactide (PLLA), polyDL-lactide (PDLLA) etc. have been successfully combined with amorphous CaP,
bioglass and HAp to form composite biomaterials with high porous structures [28-30].
Besides, the incorporation of biomolecules (proteins) by surface modification accelerated
local bone growth and healing [31].
Although nanocomposite biomaterials have shown some promising advantages in
particular hard tissues treatment, the use of composite biomaterials is still at an early
stage: the mechanical properties are still lower than those of bone; for example the
Young’s modules and tensile strength of glass-ceramic/polyethylene (PE) are 2.84 GPa
and 14.84 MPa, respectively; while the natural mechanical properties of normal cortical
bone are around 30 GPa and 150 MPa, respectively [2]. In addition, more in vitro and in
vivo studies are necessary before they are applied in clinical treatment.

1.1.5

Nano-bioceramics and Drug Delivery

With the development of nanotechnology, bioceramics currently are designed at the
nanoscale to obtain gene- and cell-activating functions to meet the requirement of third
generation biomaterials [32]. There are four main methods which are currently used to
synthesize nano-bioceramics: sol-gel method, hydrothermal method, chemical
precipitation, and solid-reaction [10].
Nowadays, open bone fractures are more and more common, even though the
development of the aseptic surgical technique, the association of bone infections after the
surgery are reported to be 7% [33], and the following treatments are more difficult.
Repeated operations to remove dead bone tissue cannot be avoided which leads to more
medical spending, more pains and higher health risks to the patients [34]. The
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conventional intake of antibiotics and anti-inflammatory drugs (oral and injection) for
prophylaxis are not effective because the perfusion rate to diseased bone site is poor.
Hence, new requirements for bioceramics, which possess the ability to deliver drugs to
local diseased bone site in order to increase the effectiveness of therapy, are increasing
[35]. After the successful application of ordered mesoporous silica in drug delivery [36]
(Vallet-Regi et al. loaded ibuprofen (IBU) into Mobil composition of matter No. 41
(MCM-41), which is a type of mesoporous silicate and alumosilicate material [37]),
highly ordered structures, high surface area, and larger pore size have been regarded as
the key factors to increase the possibilities to trap both small and large drug molecules
into the bioceramics. Since then, many new types of porous bioceramics with different
functionalities have been investigated [38, 39]; until now, a wide range of drugs
(antibiotics [40], anticancer drug [41], anti-inflammatory drug [42] and proteins [43] etc.)
have been successfully loaded into bioceramics drug carriers. In this thesis, three kinds of
drugs molecules are utilized to study the drug-carrier interactions: ibuprofen, which is an
anti-inflammatory drug, is daily used to reduce fever and treat pain or inflammation
caused by many conditions; alendronate sodium, a bisphosphonate drug, inhibits bone
resorption by osteoclasts [44] and gentamicin sulfate, a typical antibiotic drug that is
extremely effective in treating bone infections [45]. Their chemical structures are shown
in Scheme 1-1.
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Scheme 1-1 Chemical structures of ibuprofen, alendronate sodium and gentamicin
sulfate.

1.1.6

Calcium Silicate Bioceramics

Although silicate bioceramics was first proposed as SiO2-CaO-Na2O-P2O5 glass by
Hench et al. in the early 1970s [46], they are still regarded as a new family of
biomaterials, because silicon which is one of the trace element in human body, is found
to be located on the active calcification sites in bones and directly participated in the
biomineralization processes in simulated body fluid (SBF) [47, 48]. What are more
important, previous studies have shown that Ca and Si are found to stimulate osteoblast
proliferation and differentiation in vitro [49, 50]. Besides, the mechanical properties of
silicate bioceramics are higher than those of HAp ceramics; for example, the bending
strength and fracture toughness of HAp are 195 MPa and 1.3 MPa·m1/2, respectively;
while these mechanical properties of dicalcium silicate are 293 MPa and 3.0 MPa·m1/2,
respectively [51]. Hence, silicate bioceramics belong to the third generation of
biomaterials and gained more research attentions during the past few years.
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Calcium silicates (CS), which are normally regarded as a main component of cement,
have not been used as bioceramics until the last two decade. There are three kinds of
calcium silicate with different Ca/Si ratios: monocalcium, dicalcium, and tricalcium
silicate, and dicalcium silicates have five polymorphs [52]. When hydrated, the silicate
phases undergo physicochemical reactions resulting in the formation of calcium silicate
hydrates (CSH) and a soluble fraction of calcium hydroxide [53]. CSH microspheres
studied in this thesis have the crystal structure of rankinite, while CSH nanosheets
possess the crystal structure of 1.4 nm tobermorite, whose unit cells are shown in Figure
1-1. Figure 1-1(a) is the unit cell of rankinite; the calcium atoms which have seven
nearest neighbours of oxygens, are placed among the Si2O7 paired linked tetrahedra [54].
Figure 1-1 (b) shows the structure of tobermorite; it is formed by a central Ca-O sheet
(Ca is in octahedral structure which have six nearest neighbour oxygens), which flanked
on each side of silicates’ “dreierketten” chains: the silicate tetrahedra share oxygen atoms
with the Ca-O layer or neighbouring bridge silicate tetrahedra. Hydrates can either adsorb
on the surface or in the interlayer spaces [55-57]. The concentrations of Ca-OH and SiOH groups on CSH surface are extremely important because they not only determine the
nanostructure of CSH, but also are the bioactive sites for bone attachment. Ca-OH groups
located at the interlayer site or at the surface will be dominant only at high Ca/Si ratios
[56, 58].

Figure 1-1 Crystal structures of (a) rankinite and (b) tobermorite.
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Until now, CS can be fabricated into microspheres, nanowires, nanobelts etc. and all of
them have shown good biocompatibility, bioactivity, and excellent marginal adaptation
and sealing ability, hence they are primarily applied as dental repair materials [59], and
the CS application in bone treatment is still ongoing. More recently, Wu et al.
successfully incorporated drug molecules, protein and metal ions into CSH nanosheets
[60]; they found that the release rates of anticancer drug destruxin (DTX) in CSH/mPEGPLGA nanoparticles in phosphate buffered saline are different at different pH, which is
promising for cancer therapy [61]. Fan et al. [62] and Kang et al. [63] used as Eu3+ and
Tb3+ doped CS as drug carriers, which illustrate the current development of multifunction
bioceramics (drug delivery and imaging). All these results demonstrate that CS/CSH is a
type of great potential biomaterials for drug delivery.

1.2 X-ray Absorption Spectroscopy
1.2.1

X-ray Absorption Fine Structure

X-ray absorption fine structure (XAFS) spectroscopy is an elemental specific technique
which provides much information of the local structure of materials, and XAFS is not
limited to crystalline sample, it works for non-crystalline, liquid or gas phases.
Information such as formal oxidation state, coordination number, bond length, etc. can be
obtained from XAFS.
When X-ray photons are absorbed by materials, their intensities are attenuated in an
exponential function:
𝐼𝑡 = 𝐼0 𝑒 −𝜇𝑡

(1 − 1)

where I0 is the incident X-ray intensity , It is the transmitted X-ray intensity, t is the
thickness of the sample and the μ is the absorption coefficient [64, 65]. XAFS
measurements are made by monitoring the absorption coefficient (μ in cm-1) as a function
of the X-ray energy (E) of a specific element across an absorption edge of the element of
interest. Elemental specificity comes about since each atom has core level electrons with
unique energy thresholds. When the incident X-ray energy reaches the energy threshold
of a core electron, X-ray energy will be absorbed due to the increase of absorption cross
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section (σ in cm2/g) resulting in a sharp rise of μ (absorption edge). Hence, the absorption
coefficient can be written as a function of the X-ray absorption cross section as
𝜇= 𝜎 ∙ 𝜌

(1 − 2)

where ρ is the density of sample (g/cm3). Figure 1-2 shows the atomic mass
photoabsorption cross section of silver metal as a function of X-ray energy. There are
several absorption edges, labeled L3, L2, L1 and K corresponding to core level electron at
different energy levels being excited. K-edge refers to the excitation of the 1s core
electrons at threshold, L1-edge is the energy at which the 2s core electrons are excited,
and L3, 2-edge is the excitation of the 2p3/2 and 2p1/2 electrons.

Figure 1-2 Log-log plot of the mass photoabsorption cross section of silver as a
function of X-ray photon energy [66].
When the absorbing atom is surrounded by a neighbouring atom, the ejected
photoelectron can be scattered from the electrons of the neighbouring atom, and return to
the absorbing atom, in the form of a wave with the wave number (2π/λ) proportional to

10

the (E-E0)1/2. The outgoing and backscattering wave interfere with each other by
modulating the absorption coefficient (μ(E)). We call this modulation the XAFS. It
should be noted that in a free atom, there is no neighboring atom, hence no XAFS (Figure
1-3).

Figure 1-3 Illustration of outgoing photoelectron wave produced by a diatomic
system upon X-ray absorption [67].
An XAFS spectrum is typically divided into two regimes, X-ray absorption near-edge
structure (XANES) and extended X-ray fine structure (EXAFS), which are dependent on
the behaviours of electrons scattering related to the kinetic energy of electrons [68]. In
this thesis, researches are only focused on the XANES region, generally from 20 eV
below to 50 eV above the absorption edge. There are two sources for the XANES
intensity; one is the probability of a transition from initial state to a final state, which can
be described by Fermi’s golden rule; the other is the density of states (ρ) where the
excited state is embedded:
2

𝜇(𝐸) ∝ |〈𝜑𝑖 |𝐻|𝜑𝑓 〉| 𝜌

(1 − 3)

11

where φi and φf are the initial and final state wave function, respectively; H is the
interaction Hamiltonian, which includes the electric field vector of X-ray (ε) and electron
vector (r) . Hence, Equation 1-3 can be rewritten as:
2

𝜇(𝐸) ∝ |〈𝜑𝑖 |𝜀 ∙ 𝑟|𝜑𝑓 〉| 𝜌′

(1 − 4)

It should be noted that the quantum states which the electrons can be excited to should
have not only the right energy, but also have the right angular momentum; hence all the
allowed transition probability is followed by dipole transition selection rule (∆l = ± 1, ∆j
= 0, ± 1). For example, core electrons from s orbitals can be only excited to the p final
state and p core-level is excited to either d or s states, although p to d transition is
normally a dominant process, and electrons from 2p3/2, 1/2 (l = 1, j = 1/2, 3/2) may be
excited to 3d5/2, 3/2 (l = 2, j = 3/2, 5/2) [69-71].
In the XANES region, a quantitative interpretation is not often involved because the low
kinetic energy photoelectrons are more inclined to the multiple scattering phenomena.
However, materials with different structures or compositions have their unique XANES
spectra at specific absorption edges; take bioceramics as specific examples, calcium
silicate hydrate (CSH), amorphous calcium phosphate, HAp and CaCO3 show different
XANES features at the Ca K-edge, by which qualitative analysis is very reliable by
spectral “fingerprint” [72, 73].

1.2.2

De-excitation Processes

After a core electron is excited to a previously unoccupied state, which could be the
lowest unoccupied molecule orbital in molecules, states just above Fermi level in metals,
or bottom of the conduction band of semiconductors, etc., a core-hole will be created, and
several de-excitation processes will take place to fill this core-hole. There are two main
mechanisms for the de-excitation processes, Auger electron and X-ray fluorescence
ejection (Figure 1-4). After an electron from higher energy electron level drops to fill the
core-hole, the excess energy can be released by either ejection of another electron to
continuum (Auger electron) or by emission of an X-ray fluorescence photon. In either
case, a new core-hole will be created at shallower energy level, and the cascade of
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subsequent de-excitation will continue until the system is fully relaxed. These two deexcitation processes occur simultaneously however, X-ray fluorescence emission will be
dominant in the hard X-ray regime (> 10 keV), while Auger electron emission is more
likely to happen in the soft X-ray region. Major detection methods will be based on these
de-excitation processes, which will be introduced in details in Chapter 2.

Figure 1-4 Diagram of de-excitation progresses after core-electron excitation (solid
dots: electrons; hollow dot: electron core-hole).

1.3 Overview of Synchrotron Radiation
In order to conduct XAFS measurements, a tuneable X-ray source is essential, which can
be provided by synchrotron radiation. When high energy electrons are moving in a
circular orbit at near the speed of light, they will emit electromagnetic radiation tangential
to the orbit. This kind of radiation is called synchrotron radiation or synchrotron light [68,
74]. The electromagnetic radiation power (P) generated by high speed electrons when
changing directions can be expressed by Equation 1-5:
𝑃=

2 𝑒 2 𝑐 𝐸4
3 (𝑚0 𝑐 2 )4 𝜌2

(1 − 5)
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where e is the electron charge, c is the speed of light, E is the energy of the electron in
GeV, m0 is the rest mass of the particle, and ρ is the radius of the curvature of the electron
orbit. The higher the electron energy (E), the higher power of synchrotron light can be
generated. The energy loss ∆E, per electron per turn to synchrotron radiation can be
shown as
∆𝐸[keV] = 88.5

𝐸 4 [𝐺𝑒𝑉]
𝜌 [𝑚]

(1 − 6)

From Equation 1-6, the energy loss per electron per turn is around one fourth power of
the electron energy. Hence, most of synchrotron facilities are built at the energies of the
order of GeV.
The first generation synchrotron facilities were originally built for high energy physics
research until the mid-1970s, the second generation synchrotron facilities were designed
specifically as light sources, where most of beamlines are from bending magnets. Later
with the introduction of insertion devices (undulators and wigglers), the third generation
of synchrotron facilities provide higher brightness synchrotron light. So far, most of
synchrotron facilities all round the world are in third generation, like Canadian Light
Source (Canada), Advanced Photon Source (USA), and SPring-8 (Japan) [74]. A
schematic layout of a synchrotron light source is shown in Figure 1-5.
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Figure 1-5 Schematic layout of synchrotron radiation facility (focussing magnets are
left out for clarity).
First of all, bunches of electrons are generated by a heated metal oxide cathode (electron
gun), and then, they are injected into the linear accelerator (LINAC), which can
accelerate the electrons to 99.9998% of the speed of light with the energy to the order of
MeV. After that, electrons are injected into the booster ring. Dipole magnets are used to
direct electrons travelling around the booster ring, while quadrupole magnets can focus
and defocus the electrons and keep them in the desired orbit and maintain the stability of
the electron beam. After the electrons get enough energy (GeV), they are transferred into
the storage ring, where the electrons will circulate for several hours at nearly the speed of
light. In the third generation storage rings, two kinds of insertion devices, known as
wigglers and undulators were further developed. Basically, they consist of many periods
of alternating magnets to deflect the directions of high energy electrons rapidly. The
wiggler can produce a continuum of radiation that can be regarded as the superposition of
the bending magnet radiation with higher flux, whereas the undulator takes advantage of
the phasing/interference effects to produce more collimated, synchrotron light (Figure 16). Hence, electromagnetic radiation will be produced either by the bending magnets
(tangential to the orbit) or by insertion devices at straight sections. Moreover, a radio
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frequency (RF) cavity in the straight section is applied to restore the energy loss of
synchrotron radiation [68].

Figure 1-6 Emission pattern of bending magnet (a), wiggler (b) and undulator (c)
(1/γ is the opening angle, and N is the number of magnets) [68].
Under the Lorentz force of bending magnet or insertion devices, the synchrotron light is
emitted by the trajectory altered high energy electron, with a spatial distribution, defined
by opening angle (γ-1), where γ is the ratio of the mass of a relativistic electron to its rest
mass.
𝛾=

𝑚
𝐸
=
= 1957𝐸 (𝐺𝑒𝑉)
𝑚0
𝑚0 𝑐 2

(1 − 7)

The reason why synchrotron radiation is energy tuneable is because of the broad energy
spread (∆ESR) of the photon spectrum, which can be explained by using an approximation
based on Heisenberg’s uncertainty principle. As mentioned above, when the trajectory of
high energy electrons are bended by magnet, electromagnetic radiation is emitted with a
pulse of duration ∆t. The length of pulse can be determined by a consideration shown in
Figure 1-7.

16

Figure 1-7 Duration of the light pulse produced by a single electron in an ideal orbit
seen by an observer [68].
The light is first seen at point A where the electron is at an angle of 1/γ to the observer.
At point A’, light is last seen the angle is -1/γ. So the pulse length of radiation is the time
difference between the electron (te) and photon (tγ) going from point A to A’ (equation 18). According to Heisenberg’s uncertainty principle, Equation 1-11 can be derived; and
thus, for a typical GeV synchrotron facility, the energy spread is around keV. Hence, this
wide energy range provides the tunability of synchrotron radiation from a bending
magnet.
1
2𝜌 2𝜌 sin (𝛾 )
4𝜌
∆𝑡 = 𝑡𝑒 − 𝑡𝛾 =
−
≈
𝛽𝛾𝑐
𝑐
3𝑐𝛾 3
𝛽 = 𝑣⁄𝑐

(1 − 8)
(1 − 9)

∆𝐸𝑆𝑅 ∙ ∆𝑡 ≥ ℏ⁄2

(1 − 10)

3ℏ𝑐𝛾 3
8𝜌

(1 − 11)

∆𝐸𝑆𝑅 ≥
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Besides tunable energy (energy ranges from IR to hard X-ray) and highly collimated light
(very narrow opening angle 1/γ), compared with conventional characterization
techniques, synchrotron radiation has a couple of advantages which make synchrotron
radiation more powerful in materials analysis despite they are not utilized in this thesis.
First is the polarization. Synchrotron light can be linearly polarized in the orbit plane,
and elliptically polarized out of the orbit plane. Hence, polarization is a very important
property of synchrotron radiation; it provides possibilities for the study of magnetic and
optical circular and linear dichroism. Second is the time structure of the synchrotron
light. Because of the use of radio frequency cavity to replenish the energy loss of
electrons in the storage ring, it produces bunches of electrons whose length determines
the pulse width of the synchrotron light (in nanoseconds). For example, the Canadian
Light Source ring has a 35 ps pulse width with a repetition rate of 570 ns. This unique
property allows for conducting time-resolved experiments [68, 75].

1.4 Research Motivations and Thesis Outline
Despite the reported studies of bioceramics in drug delivery, enhancing drug loading
capacities of drug carriers and controlling drug release kinetics are still challenges in the
drug delivery field, which would be largely influenced by the interaction between drug
molecules and drug carriers. Currently, only a few researches have been systematically
carried out on the interaction study between drug molecules and drug carriers on the
molecular level, which is due to the limitation of conventional characterization
techniques. Moreover, although many characterization methods have been used in the
study of the transformation mechanisms from CS to HAp, the mechanism of
biomineralization of CS is still not completely clear so far because some of the initial
products are amorphous and in a low amount. From the introduction of XAFS described
above, it is certain that XAFS is a powerful tool in the investigation of ceramic
biomaterials in drug delivery applications because XAFS is elemental specific and
sensitive to the subtle changes of chemical environment of absorbing atoms. For
example, changes of the electronic structures of the bioceramics before and after drug
loading can be tracked by comparison of the XANES spectra, thus a more comprehensive
understanding of how drug molecules interact with different functional groups in drug
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carriers will be obtained. This information will provide foresights into the
functionalization and engineering of bioceramics to enhance drug loading capacities.
The thesis outline is as follows: Chapter 1 provides a general introduction of
biomaterials, bioceramics, descriptions of X-ray absorption fine structure, and overview
of synchrotron radiation. Chapter 2 provides the synchrotron radiation instrumentations,
detection methods, XANES modelling processes, and related analysis techniques which
were used in the research. Chapter 3 discusses the interactions between calcium silicate
hydrate (CSH) with different morphologies and ibuprofen (IBU) molecules by using Xray absorption near edge structure (XANES) spectroscopy. In Chapter 4, mapping of an
individual mesoporous CSH microsphere before and after the loading of IBU and the
interaction between individual drug carrier and drug molecules are presented
simultaneously by scanning transmission X-ray microscopy (STXM). Chapter 5 reports a
systematic and comparative study to investigate the interactions between CSH drug
carriers and different drug molecules in order to reveal the relationship of interactions
and drug loading capacities. Chapter 6 presents the XANES and STXM studies of
biomineralization mechanisms of CSH microspheres upon IBU release in SBF. In
Chapter 7, the effects of block copolymer on drug loading capacities of CSH/polymer
composites are studied using XANES spectroscopy. Chapter 8 contains the summaries
from Chapter 3 to7 and a description of proposed future work.
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Chapter 2

2

Experimental Facilities and Methodologies

2.1 Experimental Facilities
2.1.1

Shanghai Institute of Ceramics

Shanghai Institute of Ceramics of the Chinese Academy of Sciences (SICCAS) which
locates in Shanghai, China, was founded in 1959 under Chinese Academy of Sciences
(CAS), while the history of SICCAS can be dated back to 1928 when the Engineering
Institute of the National Central Academy was founded. Its main research areas are
focused on high performance ceramics and superfine microstructures, structural ceramics
and composites, inorganic functional materials and devices etc. So far, SICCAS has won
49 national-level awards, applied 650 patents [1]. In this thesis, all the samples
preparations and parts of characterizations (such as XRD, FTIR etc.) are conducted in
SICCAS under the supervision and support of our collaborator Prof. Ying-Jie Zhu.

2.1.2

Canadian Light Source

Canadian Light Source (CLS) which is a third generation synchrotron light source is
located at the University of Saskatchewan, Saskatoon, SK, Canada. It is assembled by a
250 MeV electron linear accelerator (LINAC), a booster ring to increase the electron
beam energy to 2.9 GeV, and the main storage ring which operates at the energy of 2.9
GeV and the current of 500 mA. The radio frequency (RF) cavity which operates at 500
MHz is installed to restore the electrons energy loss [2].Figure 2-1 shows the schematic
layout of the CLS beamlines. Currently 14 operating beamlines which provide photon
energy range from Far IR to hard X-ray are designed to meet specific experimental
techniques. In this thesis, three beamlines, Spherical Grating Monochromator (SGM)
beamline, Soft X-ray Spectromicroscopy (SM) beamline and Soft X-ray
Microcharacterization Beamline (SXRMB) are used for XANES and STXM experiments.
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Figure 2-1 Schematic layout of the CLS beamlines (courtesy of Canadian Light
Source Inc.) [3].

2.2 Beamlines
2.2.1

Spherical Grating Monochromator (SGM) Beamline

The SGM beamline (11ID-1) at CLS is an undulator based beamline, which covers the
energy range from 250 eV-2000 eV. It is a dragon-shape beamline which is based on
Chen’s design [4], and its layout is shown in Figure 2-2. Three gratings are available to
choose for the desired energy range: low energy grating (LEG): 250-700 eV, medium
energy grating (MEG): 450-1250 eV and high energy grating (HEG): 740-2000 eV. The
energy resolution (E/ΔE) is greater than 5000 at energy below 1500 eV with spot size of
1000 μm x 100 μm (Horizontal x Vertical). The beamline flux (normalized to 100 mA) is
greater than 1012 at 250 eV and exceeds 1011 up to 1900 eV [5]. The beamline contains
two endstations, noted as the EA1 and EA2, respectively. EA1 is designed for
photoemission studies, and EA2 is for X-ray absorption measurement. All the XAFS
experiments at SGM beamline in this thesis are conducted in endstation 2 (EA2).
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Figure 2-2 Layout of SGM beamline at CLS [6].
The SGM operates on the principle of grating diffraction,
𝑛𝜆 = 𝑑(sin 𝛼 + sin 𝛽)
𝑑=

𝑊
𝑁

(2 − 1)
(2 − 2)

where n is the order of the diffraction; α and β are the incidence and diffraction angles,
respectively; d is the distance between the grating lines; W is the ruled width and N is the
number of grating lines. Hence, the incident non-monochromatic light hits the grating at a
grazing angle (α), and different energy gets diffracted at different angles (β), and X-ray
photon energy is selected by rotation of the grating monochromator in order to make the
exit beam to a fixed angle (Figure 2-3(a)). This beamline is well suited for the XANES
spectroscopy of low Z element K-edges, such as carbon, nitrogen, oxygen, and the Ledge of the first row (3d) transition metals.
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Figure 2-3 Schematic illustration of (a) plane grating monochramtor and (b) double
crystal monochromator (DCM).

2.2.2

Soft X-ray Microcharacterization Beamline (SXRMB)

The SXRMB (06B1-1) is a bending magnet based beamline, with an energy rage from
1.7 to 10 keV and the spot size (Horizontal vs. Vertical) of 300 μm x 300 μm (Figure 24).
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Figure 2-4 Layout of SXRMB at CLS [7].
The energy selection is based on Bragg’s law by using double-crystal monochromators
(DCM).
𝑛𝜆 = 2𝑑 sin 𝜃

(2 − 3)

where n is the order of the diffraction; λ is the wavelength of the light; θ is the scattering
angle; d is the lattice spacing of a crystal, which is determined by the crystal plane
(Miller index (h, l, k)) (Equation 2-4).
𝑑=

1
√ℎ2 + 𝑘 2 + 𝑙 2

(2 − 4)

Two same perfect crystals are installed parallel to each other, and there are two sets of
crystals equipped in SXRMB (Figure 2-3(b)): InSb (111) crystals are used for photon
energy below 3.7 keV; and Si (111) crystals are used for energy up to 10 keV. The
energy is selected by rotating and translating of both crystals to keep the outgoing bean is
at a fixed angle. The energy resolutions (E/ΔE) of two sets of crystals are different:
InSb(111) has a resolution around 3000; while Si(111) has a resolution of 10,000 [8].
SXRMB is ideal for the XANES of the K-edge of many elements, specifically Si, P and
Ca K-edge in this research; and L-edge and M-edge of the 4d and 5d transition metals.

2.2.3

Soft X-ray Spectromicroscopy (SM) Beamline

The SM beamline (10ID-1) is a spectromicroscopy beamline based on a collimated plane
grating monochromator optimized for 130-2500 eV range and the normal spectral
resolution (E/ΔE) is 3000 (can be higher than 10,000) (Figure 2-5). Similar to the SGM
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beamline, it is split into two endstations: scanning transmission X-ray microscope
(STXM) and roll-in X-ray photoemission electron microscopy (X-PEEM). This beamline
covers C, N, O, Si, P, and Al K-edge and L-edges of all the 3d transition metals; hence it
is essential for the biological, environmental science [9]. In this thesis, all the synchrotron
experiments are conducted at the STXM endstation.

Figure 2-5 Layout of SM beamlines at CLS (courtesy of Canadian Light Source
Inc.) [10].
In STXM endstation, a Fresnel zone plate is used to further focus monochromatic X-rays
to a small spot size (~30 nm) (Figure 2-6). To generate an image, the specimen is rasterscanned in the focused X-ray under the control of computer. The transmitted photons are
collected by X-ray detector behind the specimen. Micro-spectra are measured by holding
the beam at the spot of interest on the sample while the photon energy is scanned.

Figure 2-6 Schematic illustration of STXM.
For quantitative analysis, XANES spectra were obtained by converting the transmitted
signal to optical density (OD) based on Beer-Lambert Law:
𝐼𝑡
𝑂𝐷 = − ln( ) = 𝜇 ∙ 𝜌 ∙ 𝑡
𝐼0

(2 − 5)
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where I0 and It are the incident and transmitted X-ray photon flux (photons), respectively.
μ is the energy dependent mass absorption coefficient (cm2/g), ρ is the density (g/cm3) of
the material, and t is the sample thickness (nm). Then these spectra were converted to
absolute linear absorbance scales (optical density per nm thickness sample). The
elemental linear X-ray absorption, which neglects interactions such as bonding among the
atoms, is calculated by aXis2000 using Equation (2-5) and (2-6):
𝜇=

𝑁A
∑ 𝑥𝑖 ·𝜎𝑎𝑖
MM

(2 − 6)

i

where NA is the Avogadro’s number, MM is the molecular weight of a compound
containing xi atoms of type i, σai is the atomic photo-absorption cross section (cm2/atom)
for type i atom. Then, the thickness was obtained by comparing the OD of each pixel in a
STXM image and reference spectra [11].

2.3 Detection Modes
There are several detection modes to measure XAFS spectra, shown in Figure 2-7:
transmission mode, total electron yield (TEY) mode and fluorescence yield (FLY) mode.
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Figure 2-7 Illustration of XAFS detection modes: (a) transmission, (b) electron and
X-ray fluorescence yield (TEY is detected by monitoring the sample neutralization
current).
In transmission mode measurement, the intensities of the incident and transmitted X-rays
are typically measured using ionization chambers which are filled with N2 gas before and
after the sample, respectively, and the absorption coefficient as a function of excitation
energy, μ(E) is calculated directly from the ratio of I0 to It using Beer’s Law (See
Equation 1-1). However, the thickness of sample cannot be too thick; otherwise all the
photons will be adsorbed by the samples themselves, and concentration of element of
interest cannot be too low (must be larger than 10% wt.), or the absorption is not constant
throughout the sample. Thus transmission mode is suitable for the measurement of
uniform samples which can be made into thin films (such as metal foils or pure minerals)
[12].
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If the samples cannot be made thin enough for transmission, as is often the case for low Z
elements or the element concentration is too low, electron or fluorescence yields are
alternative preferred detection modes for measuring XAFS. As mentioned in Section
1.2.2 of Chapter 1, several de-excitation processes (Auger electron process, secondary
electron process and X-ray fluorescence process) take place simultaneously in order to
fill the electron core-hole. TEY measures all the electrons ejected from the samples,
including photoelectrons, Auger electrons and secondary electrons. It is detected by
monitoring the sample neutralization current (to ground) and is proportional to the
absorption coefficient [13]. It should be noted that TEY is a surface sensitive technique,
usually detecting a sample surface with a few nm deep because the electron escape depth
as a function of their energy is quite small [14].
In FY measurement, the absorption coefficient is also directly proportional to the
intensity of X-ray fluorescence photons. There are several types of detectors that have
been used for collecting X-ray fluorescence, such as multi-channel plates, solid state
detectors and Si drift detectors. Compared with TEY, the attenuation length of the
fluorescence X-ray is quite larger compared to that of an Auger or secondary electron,
allowing the bulk of the sample to be probed. However, the self-absorption effect which
suppresses or inverses the peaks in the spectra and makes FY nonlinear to the absorption
coefficient is commonly seen at the soft X-ray region for low Z elements or the sample is
too concentrated. It often occurs when the penetration depth of the X-rays varies strongly
near an X-ray absorption edge. Recently, this effect can be partially overcome with the
development of inversion partial fluorescence yield (IPFY) by using energy-dispersive
fluorescence detector [15].

2.4 FEFF Simulations
FEFF is a computer code based on Real Space Multiple Scattering Theory-it allows the
mathematical modeling of XANES and EXAFS. It originated from Prof. John Rehr’s
group at the University of Washington and has been upgraded to the present versionFEFF9 over a period of more than three decades. FEEF is commonly accepted in the
literature. This theory can be derived from the real-space Green’s function approach [16].
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The amplitude of XAFS is given by Equation 2-7 (similar to the origin of EXAFS
equation) [17]:
𝜒(𝑘) = 𝑆02 ∑
𝑅

−2𝑅⁄
|𝑓𝑒𝑓𝑓 (𝑘)|
2 2
𝜆𝑘 𝑒 −2𝜎 𝑘
sin(2𝑘𝑅 + Φ𝑘 ) 𝑒
2
𝑘𝑅

(2 − 7)

where 𝑆02 is the amplitude reduction; k is the wave-vector of the photo-electron and feff is
the effective scattering amplitude. The structural parameters include the atomic radius R.
The dependence of the oscillatory structure on atomic radius and energy is reflected by
the sine function. The decay of the wave due to the mean free path or core-hole life time
of the photoelectron is described by the exponential term 𝑒
factor is given by 𝑒

−2𝜎2 𝑘 2

−2𝑅⁄
𝜆.

The Debye-Waller

, which is due to thermal and static effects and is negligible in

XANES when 𝜎 2 𝑘 2 ≤ 1. This equation has been calculated including options in the
FEFF code and is used to analyze XAFS data.
To set up a calculation, the positions of the atomic positions are needed to be input into
the FEFF software. The clusters can be generated by the crystal parameters, including the
space group, unit cell parameters, and the atomic coordination in the unit cell, etc. A
FEFF calculation starts with two basic tasks: calculation of the potentials, followed by
calculation of the scattering phase shifts. Using these phase shifts, scattering paths are
found and their scattering amplitudes can be calculated. For XANES calculation, it can
be approached by full multiple scattering. Finally, these scattering amplitudes are
combined and generate the calculated XAFS spectra [18].

2.5 Linear Combination Fitting (LCF)
ATHENA is a graphical front end to Matt Newville’s IFEFFIT library written entirely in
the Perl programming language and using the PGPLOT graphical library for data display.
It is designed to provide high quality analysis with a highly usable interface. It has many
capabilities to process and plot large quantities of data, including energy calibration, k-,
R- space transformation, peak fitting, etc., among which, linear combination fitting (LCF)
of standard to XANES data is one of the unique functions. This fitting can be done using
normalized μ(E) spectra. This analysis could help interpret the kinetics of a series of
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spectra measured during a chemical reaction. By fitting each intermediate spectrum as a
linear combination of the different standard spectra, one can determine the species and
the relative amount of standards in a heterogeneous sample. In order to have a best result,
spectra normalization is very important, including background removal, energy threshold
determination μ0(E), and pre- and post-edge selection.
LCF is based on a non-linear, least-squares minimization procedure. After fitting, the
fitting result parameters will be shown along with the R-factor, which should be smaller
than 1. The R-factor reported in the text box is:
𝑅=

𝑆𝑢𝑚 ((𝑑𝑎𝑡𝑎 − 𝑓𝑖𝑡)2 )
𝑆𝑢𝑚 (𝑑𝑎𝑡𝑎2 )

(2 − 8)

where the sums are over the data points in the fitting region.
Interpretation of the statistical parameters requires the knowledge about the system which
is measuring. The results of sample fractions must be meaningful in the context of any
external knowledge about the system [19].

2.6 Other Characterization Techniques
2.6.1

Brunauer-Emmett-Teller (BET) Theory

This theory was first established in 1938 [20], and so far it has been widely used to
determine the specific surface areas of materials. It uses the adsorption of chemically
inert gases, such as helium, nitrogen, to measure the total surface area contained in or on
micropores, mesopores, macropores and flat surfaces. The BET equation can be
expressed as
1
𝑐−1 𝑝
1
=
+
𝑝0
𝑣𝑚 𝑝0 𝑣𝑚 𝑐
𝑣[( ⁄𝑝) − 1]

(2 − 9)

where p and p0 are the equilibrium and saturation pressures of the gas, respectively; v is
the volume of the adsorbed gas; vm is the volume of gas adsorbed when the entire
adsorbent surface is coved with a complete unimolecular layer; c is the constant. Hence,
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Equation 2-9 can be plotted as a straight line (y-axis: 1/v[(p0/p)-1] and x-axis: p/p0). Thus,
vm and c can be calculated based the linear relationship and surface area of the solid can
be calculated based on the value of vm:
𝑆=

𝑣𝑚 𝑁𝜎
𝑉

(2 − 10)

where V is the molar volume of the gas, N is the Avogadro number and σ the area
covered by one layer gas molecules [21].

2.6.2

Thermalgravimetric Analysis (TGA)

TGA is a thermal analysis method in which changes of materials mass are measured as a
function of increasing temperature (at a constant heating rate). It can provide many
physical and chemical phenomena of samples, such as vaporization, adsorption,
dehydration, decomposition etc. [22]. It can be applied into measurement of weight of
organic component; determine the purity or compositions of minerals; and some kinetic
reactions involving weight loss. There are several features in the TGA curve:
1. The horizontal or plateau portion of the curve indicates the constant weight.
2. The curved portion means the weight loss; the steepness of the curve indicates the
rate of weight loss
3. An inflection (minimum of 𝑑𝑤⁄𝑑𝑡, but not zero) may imply an intermediate
compound formation.
A TGA instrument consists of a sample pan that is supported by a precision balance, and
a furnace is heated during the experiment. The mass of the sample is monitored during
the experiment. In this thesis, TGA was utilized to compare the weight loss before and
after drug loading to calculate the drug loading capacities in CSH drug carriers.
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2.6.3

Inductively Coupled Plasma Optical Emission Spectrometry
(ICP-OES) Analysis

ICP-OES is an analytical technique used for the detection of trace elements. It is based on
the spontaneous emission of photons from atoms or ions that have been excited in a radio
frequency discharge. Inductively coupled plasma (ICP) has a temperature of
approximately 10,000 K, so the aerosol which is converted from the sample, is quickly
vaporized. Liquid and gas samples can be injected into the plasma directly, while solid
samples require acid dissolution. Elements are easily liberated as free atoms in the
gaseous phase and further excited by the plasma. The excess energy is going to be
released by the emission of photons which have unique energies. Thus the wavelength of
the photons can be used to identify the elements from which they originated. The total
number of photons is directly proportional to the concentration of the originating element
in the sample [23]. The number of elements that can be measured by ICP-OES is around
70, including alkaline and alkaline earth elements, rare earth elements, transition metals
and some low Z elements (B, C, N, Si, P, Cl etc.). In this thesis, ICP-OES is used to
determine the Ca, P, Si concentration during the CSH biomineralization upon ibuprofen
(IBU) release in Chapter 6.
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Chapter 3

3

Drug-Carrier Interaction - Tracking the Local Structure
of Calcium Silicate upon Ibuprofen Loading with X-ray
Absorption Near Edge Structure (XANES)

3.1 Introduction
Ceramic devices are generally suitable candidates for biological and medical applications
due to their compatibility with human tissues [1]. For example, calcium phosphate [2],
hydroxyapatite [3], alumina [4], zirconia [5] etc. have been studied extensively and these
studies have made significant contributions to bone tissue engineering and drug delivery.
Although calcium silicate hydrates (CSH) were just regarded formerly as simple
components of glass, they have been shown recently to be excellent candidates for the
application of bone regeneration due to their good bioactivity, biocompatibility and
biodegradability [6-9].
Despite the interest, most of the researches concentrate on the development of new types
of drug carriers, innovative synthesis methods [3, 6, 10] and drug release kinetics [10,
11], little is known or have researches been carried out on the interactions between drug
molecules and drug carriers on the molecular level. Undoubtedly, the interactions
between drug molecules and their carriers are fundamental and valuable for drug carriers
engineering optimizations. Using differential scanning calorimetry (DSC), powder X-ray
diffraction (PXRD) and Fourier transform infrared spectroscopy (FTIR), Madieh et al.
[12] reported that silanol groups on the surface could interact with functional groups of
drug molecules via hydrogen bonding, and Wu et al. [10, 13] noted that calcium ions
could possibly interact with the carboxyl groups of ibuprofen molecules.

* A version of this chapter has been published in Phys. Chem. Chem. Phys. 2013, 15,
15033-15040. Reproduced by permission of the PCCP Owner Societies. DOI:
10.1039/C3CP50699A
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XANES is now a well-established element and chemical specific technique and can also
be modelled with theory. Thus, we can track the changes of the electronic structure of the
drug delivery materials before, during and after drug loading by investigating the local
environment of the atoms of interest using XANES, such as Si and Ca in this case, and
gain a more comprehensive understanding of how drug molecules interact with different
functional groups in drug carriers and their implications on local structure of the carrier
framework and their drug loading capacities. In this chapter, we report the XANES study
at both the Ca and Si K-edge of the interactions between a model drug, ibuprofen (IBU)
and calcium silicate hydrate carriers with different morphologies.

3.2 Experimental
3.2.1

Synthesis of Materials

Calcium silicate hydrate (CSH) mesoporous microspheres formed by self-assembly of
nanosheets were prepared according to a sonochemical method [10]. Briefly, 5 mL of a 4
M NaOH aqueous solution and 2.0 mL of tetraethyl orthosilicate (TEOS) were added into
500 mL of a 0.03 M Ca(NO3)2 aqueous solution under magnetic stirring at room
temperature. The resulting mixture was ultrasonically irradiated for 1 h under ambient
conditions with a high-intensity ultrasonic probe with the power of 200 W (Ti-horn, 27
kHz, Hangzhou Success, China) immersed directly in the solution.
The CSH nanosheets were synthesized using a controlled precipitation reaction between
calcium salt and silicate salt [13]. 3.0 mmol Na2SiO3·9H2O was dissolved in 50 mL
deionized water, into which 5.0 mL of a 0.6 M Ca(NO3)2 aqueous solution was injected at
a constant addition rate of 2.5 mL· h−1 at room temperature under magnetic stirring. The
resulting reaction system was aged at room temperature under stirring for 3 h. Then the
product was centrifuged, washed with deionized water and absolute ethanol several
times, and dried at 60°C. The amorphous CSH nanoparticles were synthesized by using a
rapid precipitation reaction between calcium salt and silicate salt.
For the preparation of the anhydrous calcium silicate (CS) counterparts, the assynthesized CSH powder was heated at a rate of 2 °C/min from room temperature to 700
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°C, and maintained at this temperature for 2 h, then cooled at the same rate to room
temperature.

3.2.2

IBU Drug Loading

The carrier (0.67 g) was added to 50 mL IBU hexane solution (~40 mg mL-1) in a flask at
room temperature. The flask was immediately sealed to prevent hexane from evaporation,
and the mixture was treated by ultrasound for several minutes. Then the flask was
oscillated at a constant rate of 160 rpm at 37 °C for 24 h. The product was separated by
centrifugation, washed with hexane once, and dried at 60 °C.

3.2.3

BET Specific Surface Areas (SSAs) Measurements

The specific surface areas (SSAs) of CSH carriers before and after IBU loading were
measured with a surface area and porosimetry instrument (Gold APP, V-Sorb 2800P).

3.2.4

UV-Vis Experiments

The IBU hexane solutions before and after the IBU loading with different carriers were
analysed by UV-Vis absorption at the wavelength of 263 nm. The UV-Vis absorption
spectra were performed on a spectrophotometer (Techcomp, UV2300).

3.2.5

Fourier Transform Infrared (FTIR) Measurements

Fourier transform infrared (FTIR) spectra were recorded using the KBr technique on a
FTIR spectrometer (FTIR-7600, Lambda, Australia).

3.2.6

In Vitro IBU Drug Release

The as-prepared IBU-loaded carriers were compacted into disks (0.1 g each, d = 13 mm)
at a pressure of 3 MPa. Then each disk was immersed in 200 mL phosphate buffered
saline (PBS) at 37 °C under shaking at a constant rate of 140 rpm. The IBU release
medium (2.0 mL) was extracted for UV-Vis analysis at the wavelength of 263 nm at
given time intervals and replaced with the same volume of fresh PBS which was
preheated to 37 °C.
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3.2.7

X-ray Absorption Near Edge Spectroscopy (XANES)
Experiments

XANES measurements were conducted at the Canadian Light Source using the Soft Xray Microcharacterization Beamline (SXRMB), which is equipped with a double crystal
monochromator with two sets of interchangeable crystals operating with an energy range
of 1.7 to 10 keV. The InSb (111) crystals were used for the Si K-edge XANES
measurements while the Si (111) was used for the Ca K-edge XANES. The detection
modes are total electron yield (TEY) and X-ray fluorescence yield (FLY), tracking
surface and bulk sensitivity, respectively. Herein we only use TEY XANES for the
discussions because both TEY and FLY are the same since the specimens are
homogeneous and optically thin and FLY shows no detectable thickness effects.

3.2.8

Real Space Multiple Scattering Theory - Calculation by
FEFF9

The crystal structure of Ca3Si2O7 is modelled to have the structure of rankinite [14], and
have space group symmetry of 𝑃21 /𝑎 with lattice constants of a=10.557Å, b=8.885Å, and
c= 7.858Å, α=90°, ß=119.586°, γ=90°. The locations of the atoms in Ca3Si2O7 are shown
in Table 3-1.
Table 3-1 Atomic coordinates of rankinite.
Site
Ca1
Ca2
Ca3
Si1
Si2
O1
O2
O3
O4
O5
O6
O7

x
0.0071
0.1677
0.3403
0.2948
0.0903
0.3579
0.1782
0.4105
0.2007
0.0970
0.1451
0.9299

y
0.0552
0.5745
0.9034
0.2357
0.2145
0.4038
0.2344
0.1016
0.1629
0.3857
0.1487
0.1536

z
0.2893
0.2083
0.2839
0.4314
0.9843
0.4229
0.5033
0.5523
0.2120
0.9810
0.8437
0.9394

The XANES (X-ray Absorption Near Edge Structure) spectra of the cluster of the
Ca3Si2O7 compounds with this crystal models have been calculated by the multiple
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scattering theory using the FEFF9 code [15]. This theory is based on the real-space
Green`s function approach [16].

3.3 Results and Discussion
3.3.1

Morphologies of Calcium Silicate Samples

All calcium silicate samples were characterized by transmission electron microscopy
(TEM, Philips CM-10 Transmission Electron Microscope) at the Biotron, University of
Western Ontario (Figure 3-1). Here, only the TEM images of amorphous CSH (Figure 31(a)), CSH nanosheets (Figure 3-1(b)) and CSH mesoporous microspheres (Figure 31(c)) are shown because no significant differences either from anhydrous samples or from
the samples with IBU can be observed.

Figure 3-1 Morphologies of calcium silicate hydrate: (a) amorphous CSH, (b) CSH
nanosheets, (c) CSH mesoporous microspheres.

3.3.2

Ibuprofen Loading in CSH Drug Carriers

The UV-Vis absorption spectra of the hexane solution containing ibuprofen before and
after ibuprofen loading in different carriers are shown in Figure 3-2. One can see that the
absorption spectra of ibuprofen in hexane solution show the characteristic absorption
peaks, for example, at 263 nm, which are similar to those reported in the literature [17].
The significant decrease in the absorbance after the drug loading indicates that the drug
has been loaded into the carriers with a high drug loading capacity.
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Figure 3-2 UV-Vis absorption spectra of the IBU hexane solution diluted 50 times
before and after the IBU loading with different carriers.
To further illustrate that IBU has been loaded into CSH carriers successfully, the BET
specific surface areas (SSAs) of the CSH carriers without and with the IBU loading are
listed in Table 3-2. The SSA of CSH nanosheets is measured to be 462 m2/g, which is
ultrahigh for calcium silicate materials, and it is even higher than that of mesoporous
wollastonite calcium silicate (405 m2/g) reported previously [18]. It can be seen that the
SSAs of CSH carriers greatly decrease after the IBU drug loading, indicating that the
drug IBU has been successfully loaded into the nanocarriers. The IBU drug loading
capacities of the CSH nanocarriers, obtained from the UV-Vis absorption analysis, are
also listed in Table 3-2. One can see that the IBU drug loading capacities of the CSH
carriers are very high, which are usually higher than those reported in the literature [1921]. The IBU drug loading capacities of the CSH carriers, expressed in the unit of mg/m2,
are also presented in Table 3-2.

45

Table 3-2 BET specific surface areas (SSAs) of CSH carriers without and with IBU
loading and the IBU loading capacities.
CSH carriers

CSH nanosheets
CSH microspheres
Amorphous CSH

SSA
without
IBU
loading
(m2/g)
462
253
107

SSA with
IBU
loading
(m2/g) [a]

IBU loading
capacity
(gIBU/gcarrier) [b]

IBU loading
capacity
(mgIBU/m2carrier)

12
22
17

~1.7
~2.2
~2.0

~3.7
~8.7
~18.7

[a]

It stands for the SSA of the CSH-IBU nanocarrier drug delivery system other than the single
nanocarrier.
[b]
IBU loading capacity is obtained from the UV-Vis absorption analysis using the method of
the standard concentration curve at the absorbance of 263 nm.

3.3.3

XANES Studies of the Interactions between CSH and IBU

In order to have a comprehensive image of the interactions between calcium, silicate ions
and IBU on the molecular level, it is necessary to understand the crystal structure of
calcium silicate hydrate drug carriers. According to the study of Wu et al. [10], the crystal
structure of CSH mesoporous microspheres is rankinite (Ca3Si2O7·6H2O), and the FEFF
XANES simulation is consistent with a rankinite structure. (Figure 3-3): the XANES
spectra for all the specimens are similar to a rankinite structure. The rankinite structure
has a layered structure, in which the silicate tetrahedra share oxygen atoms with Ca-O
layer or neighboring bridge silicate tetrahedra. Hydrates can either adsorb on the surface
or in the interlayer spaces.

46

Figure 3-3 (a) TEY XANES spectra of calcium silicate hydrate and anhydrous
calcium silicate carriers with different morphologies, comparison with FEFF
calculation; (b) Crystal structure of rankinite simulated by FEFF (green, red and
beige spheres stand for Ca, O and Si atoms, respectively).
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Figure 3-4 shows the Ca K-edge XANES of carriers of calcium silicate hydrate and
anhydrous calcium silicate with different morphologies, before (a) and after (b) IBU
loading and a standard calcium silicate hydrate. CSH and CS henceforth denote calcium
silicate with and without hydrate, respectively. From the XANES of the specimens before
IBU loading, there are four discernible XANES features, labelled from A to D as the
energy increases. The most intense peak (labelled C) is due to 1s →np transition. This is
the principal peak which follows the dipole transition selection rules. The first small
feature at the pre-edge (labelled A) can be ascribed to 1s → 3d transition, which is
commonly observed in the K-edge spectra of the first row transition metals. Shoulder B is
assigned to the 1s → 4s transition. Although formally dipole forbidden, both A and B can
still be observed due to hybridization of Ca 3d with ligand p-character states [22-24]. The
shoulder after the main resonance (labelled D) is mainly from multiple scattering
processes, it is very sensitive to the immediate surroundings of Ca.
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Figure 3-4 Ca K-edge XANES spectra of calcium silicate hydrate and anhydrous
calcium silicate carriers with different morphologies, without (a) and with (b)
loading of IBU.
The most discernible differences from XANES spectra can be observed from Figure 3-5
when we compare the drug carriers in different morphology with and without IBU
individually. First of all, we assign feature D to be closely related to the hydrates in the
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system because the feature D is not prominent from the anhydrous samples (Figure 34(a), except amorphous CSH, which is due to poor crystallinity). For the change of
feature D in Figure 3-5, which smear out in all the spectra after IBU loading, the
explanation is given as follows. The loading of IBU replaced the hydrates on the surface
or in the interlayer, changes the local ordering and then alters the multiple scattering
pathways.
Besides, close examination of the data for the IBU-loaded drug delivery system reveals a
subtle though clearly noticeable change in the edge jump region (labelled B) which
becomes more apparent in the first derivative of the spectrum (Figure 3-5(b)). What is the
most interesting is that, before drug loading (solid lines), there are only two peaks
between 4040-4050 eV but three peaks appear after the drug is loaded (dash lines); which
means the B resonance is now split into a doublet. Moreover, the change of feature D can
be also observed in the derivative spectra of CSH samples between 4055-4060 eV, which
also supports our previous discussion.

Figure 3-5 (a) TEY XANES spectra and (b) first derivative spectra of calcium
silicate hydrate and anhydrous calcium silicate carriers with different morphologies,
with and without loading of IBU.
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The possible explanation for the change of feature B is the interaction between calcium
ions and ibuprofen; the electrostatic bonding between Ca2+ and the carboxyl groups from
the IBU drug molecules lowers the local symmetry. We propose that the following
chemical reactions take place (Scheme 3-1).

Scheme 3-1 Possible interactions between calcium ions and IBU.
The H+ ions which are provided by carboxyl groups will break up the calcium silicate
structure [25]; forming silanol groups and releasing coordination deficient Ca ions
simultaneously (Scheme 3-1, 1 and 2). Calcium ions then react with R-COO- and
generate carboxylate salt (Scheme 3-1, 3). The other possibility is that the Ca-OH groups
which locate on the surface or interlayer sites [14, 26-28] react with carboxyl groups
directly (Scheme 3-2).

Scheme 3-2 Possible interactions between calcium ions and IBU.
In either case, the local environment of Ca will somewhat similar to those in calcium
acetate (Ca(Ac)2) after IBU is loaded. This notion is supported by the observation that
drug-loaded CSH and CS carriers exhibit very similar Ca K-edge XANES as that of
calcium acetate, shown in Figure 3-6. From Figure 3-6(a), all of the TEY XANES of
drug-loaded calcium silicate samples are nearly identical to that of Ca(Ac)2 monohydrate
except the shoulder D, which is from the hydrates in calcium acetate. From Figure 3-6(b),
the derivative of CSH mesoporous microspheres with IBU (dash line) is almost the same
as that of calcium acetate monohydrate (dot line) except the difference in 4055-4060 eV.
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Both the observations suggest that there is a loss of hydrates during the IBU drug loading
processes.

Figure 3-6 Comparison of drug-loaded CSH and CS carriers with calcium acetate
monohydrate powder; (a) Ca K-edge XANES total electron yield (TEY) of CSH and
CS carriers with IBU drug molecules, and (b) first derivative spectra of CSH
mesoporous microspheres before and after IBU loading.
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We now turn to the Si K-edge (Figure 3-7); all the spectra of the CSH carriers with
different morphologies without IBU are almost identical. There is only one prominent
peak (labelled A) which is identified as the Si 1s to 3p transition for silicon (IV) in a
tetrahedral oxygen ligand environment [23, 29]. This peak however is very broad, which
can be associated with chemical inhomogeneity owing to a distribution of Si (IV) sites in
chemically slight different environments. The most amazing observation is that after the
drug is loaded, a small feature (labelled B) emerges at ~2 eV below the main resonance
which sharpens considerably as if the IBU loading induces “crystallization” (ordering).
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Figure 3-7 Si K-edge XANES total electron yield (TEY) spectra of calcium silicate
hydrate and anhydrous calcium silicate nanocarriers with different morphologies,
without (a) and with (b) IBU loading.
Interestingly, compared with Figure 3-7, the main resonance not only becomes sharper
but also shifts to a higher energy (by ~ 0.5 eV) after IBU loading (Figure 3-8(a)).
Besides, the peak B in the spectra of the drug loaded carriers with hydrates (CSH) has
higher intensity (Dash lines in Figure 3-8(a1), (a3) and (a2), (a4)). Moreover, the intensity
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of peak B for the mesoporous microsphere carriers is higher than that of nanosheet
samples (Dash lines in Figure 3-8 (a1), (a2)). For the CS samples, although the presence
of B is less apparent, we can still reveal their presence from the derivative spectra (Figure
3-8(b) vertical dash dot lines).

Figure 3-8 (a) Si K-edge XANES and (b) first derivative spectra of calcium silicate
hydrate and anhydrous calcium silicate carriers with different morphologies, with
and without IBU.
These observations suggest that the samples with hydrates form more silanol groups (SiOH) on the material surface [18-21], where the IBU molecules attach to the drug carriers.
This is why the spectra of drug carriers with hydrates have a more prominent peak B. The
interaction is an esterification-like reaction (Scheme 3-3).

Scheme 3-3 Possible interaction between silanol groups and IBU.
Due to the presence of the alkyl groups, which are known to be excellent electron density
donors, in the structure (Si-O-C bonds) [30] providing better shielding, and hence we can
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observe a small peak B shifted to the lower photon energy, indicating the formation of SiOOC-R groups. However, most of the Si atoms of calcium silicate in the bulk are still in a
SiO4 tetrahedral environment and after drug loading, most of the silanol groups on the
surface probably have been reacted with carboxyl groups. As the result of this interaction,
the crystallinity of the system improves and rest of the Si atoms find themselves in a
more “regular” SiO4 like environment. That is why the main resonance turns sharper and
shifts to a higher energy (Figure 3-9).

Figure 3-9 Si K-edge XANES total electron yield (TEY) spectra of calcium silicate
hydrate mesoporous microspheres with and without IBU, compared with SiO2
powder.

3.3.4

FTIR Spectroscopy of CSH Carriers Before and After IBU
Loading

To further support the existence of the interaction between drug molecules and carriers,
the FTIR spectra of the CSH carriers without and with the IBU loading are shown in
Figure 3-10. For the carriers after IBU loading, the appearance of C–H, C=O and C–O
stretching vibration peaks indicates that IBU has been loaded on the carriers. The blue
shift of Si–O stretching vibration from 975 to 1083 cm−1 and the red shift of C=O
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stretching vibration from 1724 to 1560 cm−1 indicate the chemical interactions between
the –Si–O–Ca– groups of the carrier and –COOH groups of IBU drug molecules.
However, almost no shift of the C–O stretching vibration in IBU molecules suggests that
the chemical surrounding of C–O in the –COOH group is little changed after the drug
loading. Thus, it is inferred that there is a coordination reaction between the Ca (II) of the
carriers and the C=O group of IBU molecules during the drug loading process. The
formation of –Si–O–Ca←O=C–OH can increase the polarity of the Si–O group while
reduce the polarity of the C=O group, which results in the blue and red shifts in the FTIR
spectra mentioned above.
For the carriers before IBU loading, the absorption at around 1630 cm−1 is assigned to the
bending vibration of the adsorbed water. It can be seen that this bending vibration of H–
O–H disappears after the IBU loading, implying that there may be a replacement of
hydrates during IBU loading processes. In the case of CSH nanosheets and CSH
microspheres, the absorption at 3614 cm−1 appears after IBU loading, which is assigned
to the stretching vibration of the –O–H groups of IBU molecules, free from the hydrogen
bonds (the IBU molecules in pure IBU crystals exist in the form of dimers due to
hydrogen bonding between the O–H groups) [31].
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Figure 3-10 FTIR spectra of different CSH carriers with and without IBU drug
loading; the FTIR spectrum of pure IBU is also shown for comparison.

3.3.5

In Vitro CSH-IBU Release

Figure 3-11 shows the IBU drug release profiles of the IBU-CSH carrier drug delivery
systems in the PBS medium. For the CSH mesoporous microsphere drug delivery system,
63% of the loaded IBU was released in PBS in the first 24 h and nearly 100% was
released in a time period of 175 h. The IBU drug release curves of both CSH nanosheet
and amorphous CSH drug delivery systems are similar. For these two drug delivery
systems, ~43% of the loaded IBU was released in PBS in the first 24 h and then the drug
release slowed down, and the total drug release time lasted as long as 293 h. The
excellent sustained drug release behaviors of CSH drug delivery systems are promising
for applications in various biomedical fields.
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Figure 3-11 IBU drug release profiles of different IBU-CSH drug delivery systems in
the PBS medium.

3.4 Conclusions
In summary, we have shown that IBU can be loaded into CSH drug carriers successfully
and that there are significant interactions of the drug molecules with the carriers from
XANES spectra, accompanied by the local ordering of the system.


Calcium ions interact with carboxyl groups, generating calcium acetate like
compounds.



Besides hydrogen bonding between silicates and drug molecules, the most amazing
observation is the stronger interaction between silicates and carboxylic groups,
forming Si-O-C bonds via esterification-like reaction. Moreover, drug loading leads
to better ordering of silicates locally.



Moreover, the CSH drug delivery systems exhibit high drug loading capacities and
excellent sustained drug release behaviors, which can be potentially applied in
various biomedical fields.
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Finally, we have demonstrated that the morphology and the presence of hydrates of drug
carriers may influence the drug loading capacities. XANES is a sensitive tool to track
these effects and opens up future possibilities for the study of drug delivery, drug
targeting and drug release.
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Chapter 4

4

Imaging of Drug Loading Distributions in Individual
Microsphere of Calcium Silicate Hydrate - An X-ray
Spectromicroscopic Study

4.1 Introduction
The calcium silicate based materials are promising for applications in biomedical fields
with the advantages of having excellent biocompatibility and biodegradability [1-4].
Hence, calcium silicate hydrate (CSH) can be applied in periodontal repair and bone
augmentation because of their stimulatory effect on osteogenic differentiation of stem
cells [5]. For clinical applications, drug incorporation using CSH drug carrier allows for
not only the repair of bone defects, but also bone therapies, such as bone anti-infection,
fracture consolidation and tumor treatment [6]. Insufficient drug dose, however, is one of
the most common issues in drug delivery systems, thus it is important to ensure the
successful incorporation of drug molecules, and to determine the drug loading capacities
for the next step. Although there are many conventional methods, such as UV-Vis,
thermogravimetric analysis etc., to measure the drug loading amount in the drug carriers,
the integrity and distributions of drug molecules, which are essential to the drug delivery
and further drug release, cannot be revealed based on the conventional techniques.
Besides, the interactions between drug molecules and carriers also play a crucial role on
drug loading capacities and drug release kinetics [7, 8]. To realize this goal, it is
necessary to image the variations of the local chemical composition in an individual drug
carrier before and after drug loading. However, very few techniques can provide this
unique information.

* A version of this chapter has been published in Nanoscale 2015, 7, 6767–6773.
Reproduced by permission of The Royal Society of Chemistry. DOI:
10.1039/C4NR07471H
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Scanning transmission X-ray microscopy (STXM) [9, 10] records the X-ray absorption
features at an absorption edge of an element in a chemical environment in the
transmission mode using a nano size X-ray beam. It provides spectromicroscopy
information; thus both chemical images and detailed absorption spectroscopic features in
the near edge region of a single nanostructure can be revealed, this technique is especially
good for the low Z elements (such as C, O and N). More importantly, STXM can also
measure the absolute thickness of the specimen. It has been successfully applied to study
the iron-based Fischer–Tropsch catalyst [11], individual multi-walled carbon nanotube
[12], graphene [13], single ZnS/ZnO nano-heterostructure [14] and individual hybrid
TiO2 particles [15] by providing unique composition of nanomaterials without significant
beam damage. X-ray absorption near edge structure (XANES) spectroscopy provides
information about the structure and bonding intimately associated with the absorbing
atom and the immediate surroundings of the absorbing atom [16]. It is very sensitive to
the slight changes of surrounding environment of target atoms via the noticeable changes
of spectral features (peak energy shift, peak intensity variations, and dis/appearance of
new features, etc.) [17-19]. As a matter of fact, STXM-XANES is also suitable for drug
delivery study. For example, it is desirable to know the integrity of drug molecules,
bonding information and their distributions after loading processes. The normal area of
beam on the samples is around mm2; consequently, the information from the XANES
spectra is an average of a large area which may contain impurities from the substrate,
especially for the organic materials. The improvement of spatial resolution of STXM
overcomes the shortcoming above and provides information of isolated or individual
structures of nanomaterials. In this chapter, we report the application of STXM combined
with XANES in the chemical imaging of individual CSH mesoporous microsphere
loaded with model drug ibuprofen (IBU). The electronic and chemical structure of
selected sample regions of sub-micron dimension were obtained by spatially-resolved
XANES at the C, O, Si K-edges and the Ca L3,2-edge.
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4.2 Experimental
4.2.1

Preparation of CSH Mesoporous Microspheres

CSH mesoporous microspheres formed by the self-assembly of CSH nanosheets were
prepared via a sonochemical method [20]. 5 mL of a 4 M NaOH aqueous solution and 2
mL of tetraethyl orthosilicate (TEOS) were added into 500 mL of 0.03 M Ca(NO3)2
aqueous solution under magnetic stirring at room temperature. The resulting mixture was
ultrasonically irradiated for 1 hour under ambient conditions using a high-intensity
ultrasonic probe with the power of 200 W (Ti-horn, 27 kHz, Hangzhou Success, China)
immersed directly in the solution. The product was centrifuged (6000 rpm for 2 min) and
washed with deionised water and absolute ethanol three times, respectively. Then, the
powder was dried in air at 60 °C overnight.

4.2.2

IBU Drug Loading

The as-synthesized powder (1.0 g of CSH mesoporous microspheres) was added to a 50
mL IBU hexane solution (~40 mg mL-1) in a flask at room temperature. The flask was
immediately sealed to prevent hexane from evaporation, and the mixture was treated by
ultrasound for 2 minutes. Then the flask was oscillated at a constant rate of 160 rpm at 37
°C for 24 hours. The product was separated by centrifugation (6000 rpm for 2 min),
washed with hexane, and dried in air at 60 °C overnight.

4.2.3

Characterization

The IBU hexane solutions before and after the IBU loading were analysed by UV-Vis
absorption (Techcomp, UV2300) at the wavelength of 263 nm. Transmission electron
microscopy (TEM) images were obtained at the Biotron, University of Western Ontario
(Philips CM-10 TEM).

4.2.4

STXM Measurement

STXM measurement was conducted at the Soft X-ray Spectromicroscopy (SM) beamline
at the Canadian Light Source (CLS); SM beamline is equipped with a 25 nm outermostzone zone plate (CXRO, Berkeley Lab). The diffraction-limited spatial resolution for this
zone plate is 30 nm with a spectral resolution of 0.05 eV. Image sequence (stack) scans
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over a range of photon energies were acquired for the same sample region at the Ca L3,2edge, and Si, O and C K-edges, respectively. A few mg of the sample was dispersed in
deionised water by brief sonication, and then deposited on a copper grid to allow it to dry
in air before transferring into the STXM chamber. STXM data were analyzed using the
aXis2000 software package, which allows for detailed interactive processing of the
images and fitting the image stacks with the X-ray absorption spectra.

4.3 Results and Discussion
4.3.1

IBU Loading in CSH Microspheres

The UV-Vis absorption spectra of the hexane solution containing IBU before and after
IBU loading in CSH mesoporous microspheres are shown in Figure 4-1. One can see that
the absorption spectra of IBU in hexane show the characteristic absorption peaks of IBU,
e.g. the most intense feature at 263 nm, which are consistent with the literature [21]. After
IBU loading, a significant decrease in the absorbance of IBU in hexane solution (red
profile) indicates that the IBU drug molecules have been loaded into the drug carriers
with a high drug loading capacity.
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Figure 4-1 UV-Vis absorption spectra of the IBU hexane solution diluted 50 times
before and after the IBU loading in CSH mesoporous microspheres.

4.3.2

Morphology of Individual CSH Microsphere Before and After
IBU Loading

The morphology of the CSH mesoporous microspheres before and after IBU loading was
characterized by TEM. As shown in Figure 4-2(a), the sample before IBU loading is
composed of mesoporous microspheres formed by self-assembly of nanosheets with
diameters around 1 µm. The three-dimensional interconnected nanosheets lead to the
formation of a large number of mesopores. It should be noted that the CSH mesoporous
microspheres after IBU loading (see Figure 4-2 (b)) show a similar morphology to that
before IBU loading. Thus, TEM results clearly reveal that the morphology of CSH
mesoporous microspheres remains intact after IBU loading, and it would be significant if
we can identify the locations and distributions of IBU in the carriers.
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Figure 4-2 TEM images of CSH mesoporous microspheres before (a) and after (b)
IBU loading.

4.3.3

STXM Analysis of Individual CSH Microsphere Before and
After IBU Loading

The STXM images of CSH microspheres before and after IBU loading (Figure 4-3 and 44) are in good agreement with the TEM micrographs: no significant morphology changes
are observed from the CSH microspheres before and after IBU loading. Moreover, except
for the variations of intensities, which is due to the sample thickness, there are no
noticeable spectral differences from different CSH microspheres at Ca L3,2-edge, Si Kedge (the peak at ~1862 eV is not real, is due to the I0 glitch) and C K-edge, respectively,
indicating the uniformity of CSH microspheres. As a result, we selected individual
mesoporous microsphere for a more detailed analysis in the following study.
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Figure 4-3 (a) STXM images of CSH microspheres before IBU loading: two ROIs
were selected which represented different CSH microspheres; Red: Sphere-1, Blue:
Sphere-2. Scale bar in (a) is 1µm. (b, c) XANES spectra from each ROI displayed at
the Ca L3,2-edge (b) and the Si K-edge (c).
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Figure 4-4 (a) STXM images of CSH microspheres after IBU loading: 10 ROIs were
selected which represented different CSH microspheres. Scale bar in (a) is 1µm.
XANES spectra from each ROI displayed at (b) the C K-edge, (c) the Ca L3,2-edge
and (d) the Si K-edge.
Figure 4-5 shows the STXM images and XANES spectra taken from different regions of
interests (ROIs) of individual CSH microsphere before IBU loading at the Ca L3,2-edge,
O K-edge and Si K-edge. Several interesting features are apparent. First, at the Ca L3,2edge (Figure 4-5(c)), no significant changes were observed in the XANES spectra of
different ROIs, except that the peaks taken in the thick region (ROI-4) are broadened and
the intensity ratios of a1/a2 and b1/b2 increase a lot due to the thickness effects (saturation
phenomenon). The spin-orbit related L3 (a2) and L2 (b2) peaks before IBU loading (Figure
4-5(c)), which are located around 349.1 and 352.4 eV respectively, are due to transitions
from 2p3/2 and 2p1/2 electrons to the empty 3d states of Ca2+. The weak multiple peaks at
lower energies are due to crystal field splitting from the first coordination sphere
surrounding Ca2+ [22-26]. Thus Ca L-edge is sensitive to changes of the magnitude of
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crystal field and coordination of Ca2+. Figure 4-5(d) shows the XANES spectra at the O
K-edge. There are two discernible features, labelled “a” and “b”. The pre-edge peak “a”
is due to the Ca–O crystal field effects. The main resonance “b” at around 538 eV is from
transition from O 1s to 2p antibonding states hybridized with orbitals of the cations which
O is bound [27-29]. The Si K-edge XANES spectra are shown in Figure 4-5(e). All
spectra show the same features. The main resonance is identified as the Si 1s to 3p
transition for silicon (IV) in a tetrahedral oxygen ligand environment [30, 31]. At all the
edges, we do not observe any significant changes in spectral features in the spectra of
different ROIs, indicating that there are no chemical differences in the condensed and the
relatively thin areas.
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Figure 4-5 STXM images and XANES spectra of individual CSH microsphere
before IBU loading, (a) STXM image of individual CSH microsphere (average: 3461890 eV); (b) 4 ROIs taken from the CSH microsphere: Red: ROI-1, Cyan: ROI-2,
Blue: ROI-3, Green: ROI-4. Scale bars in (a) and (b) are 600 nm; (c), (d), (e) are
isolated XANES spectra of each ROIs displayed in (b) at Ca L3,2-edge , O K-edge
and Si K-edge, respectively.
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The analysis reported below for IBU-loaded CSH mesoporous microspheres is based on
the CSH microsphere traced in red dot circle shown in Figure 4-6(b) (taken at the Ca L3,2edge (E = 352.5 eV)). Since STXM can provide high quality images as well as high
quality absorption spectra at the C K-edge, it has been successfully applied to the studies
of carbon nanomaterials [19, 32, 33]. Therefore, it will provide chemical information of
the IBU drug molecules from the perspective of the carbon site. Figures 4-6(c) to (e)
show the STXM images and the C K-edge XANES taken from different regions of
interests (ROIs) of an individual CSH microsphere after IBU loading. As shown in Figure
4-6(e), the spectra obtained from different ROIs have identical features. The sharp peak
“a” located at 285 eV is from the carbon 1s to π* transition for the aryl rings of IBU
molecules; the peak “b” located at 288.3 eV is from the carbon 1s to π* transition for
carboxylic functional groups of IBU; the weak peak “c” located around 290 eV is
assigned to the transition from carbon 1s to σ* of the C-OH moiety of the carboxylic
group [27, 34-36]. Compared with the spectrum of IBU powder (black profile), there is
no significant change or beam damage to the IBU molecules, except that peak “c” is less
apparent after IBU loading. Based on the STXM and XANES spectra at the C K-edge, it
is certain that IBU has been successfully loaded into CSH mesoporous microspheres. We
will discuss below in details the chemistry that took place between CSH and IBU during
the drug loading process.
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Figure 4-6 STXM images of an individual CSH microsphere: (a) before and (b) after
IBU loading taken at the Ca L3,2-edge (E = 352.5 eV); (c) STXM image of an
individual CSH microsphere (average at all edges); (d) 4 ROIs taken from an
individual CSH microsphere; Red: ROI-1, Cyan: ROI-2, Blue: ROI-3, Green: ROI4. Scale bars in (c) and (d) are 500 nm; (e) XANES spectra from each ROI displayed
in (d) at the C K-edge.
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XANES spectra of the individual CSH microsphere after IBU loading in different ROIs
at the Ca L3,2-edge, Si K-edge and O K-edge, respectively are shown in Figure 4-7(a), 7(b)
and 7(c).
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Figure 4-7 XANES spectra of individual CSH microsphere after IBU loading at Ca
L3,2-edge (a), Si K-edge (b) and O K-edge (c). (ROI 1-4 are the same regions as
shown in Fig. 4-6(d)).
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Several interesting features are noticeable. First, at the Ca L3,2-edge (Figure 4-7(a)), no
significant difference in the XANES was observed for different ROIs. After IBU loading,
the XANES spectra of the four ROIs from thin areas (ROI-1 and ROI-2) to thick areas
(ROI-3 and ROI-4)) show the same features at all three edges, which means that the CSH
microspheres remain chemically uniform after IBU loading. However, having compared
the average spectra of CSH microspheres before and after IBU loading at the Ca L3,2edge, O K-edge and Si K-edge, we find discernible changes in the XANES at all edges,
as illustrated in Figure 4-8.

77

Figure 4-8 Comparison of average XANES spectra before (a) and after (b) IBU
loading at (c) Ca L3,2-edge, (d) Si K-edge and (e) O K-edge.
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The presence of Ca-OH groups in CSH has been widely reported in the literature. They
are more abundant on the surface or interlayers in order to balance the charge or
neutralize the non-bridging oxygens (NBOs) [37-40]. In our previous study, we also
illustrated that Ca–OH groups located on the surface or interlayer sites react with the
carboxyl groups of IBU directly (Scheme 4-1) [41].

Scheme 4-1 Interaction between CSH and IBU at the Ca local environment.
This interaction between Ca and IBU results in the local environment of Ca is similar to
that of calcium acetate after IBU loading. In Figure 4-8(c), there is around 0.1 eV energy
shift between the spectra before and after IBU loading. It can be ascribed to the formation
of Ca-O-C bonds after IBU loading, which distorts the structure of CSH locally by
lowering the symmetry of Ca [23]. The energy differences of ∆L3 (Ea2 - Ea1), ∆L2 (Eb2 –
Eb1) and intensity ratios of a1 to a2, b1 to b2 of the Ca L3,2-edge (see Figure 4-8(c)), are
listed in Table 4-1.
Table 4-1 ∆L3 and ∆L2 of CSH microspheres before and after IBU loading*
∆L3 (a2-a1) 𝑎1 ∆L2 (b2-b1) 𝑏1
𝑎2
𝑏2
(eV)
(eV)
Before Loading
After Loading

1.0
1.0

0.35
0.11

1.0
1.1

0.49
0.21

* The energy fine step before loading is 0.25 eV and the energy fine step after loading is 0.15
eV

It can be seen that, after IBU loading, there is no significant change in the splitting of a1
and a2 (b1 and b2 as well). That is because the CSH microsphere we synthesized is
composed of Ca3Si2O7, which has the crystal structure of rankinite as has been confirmed
in previous studies [20, 37, 42]. The calcium atom in CSH is coordinated by seven
oxygen atoms while the average coordination number of Ca in calcium acetate is reported
to be 7.5 [43-45]. Although we cannot get much information from the energy differences,
the intensity ratio of a1 to a2 (as well as b1/b2) is informative and it decreases after IBU
loading, which indicates that the magnitude of crystal field decreases after IBU loading.
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Compared to calcium silicate, the crystal field of calcium acetate is weaker because of the
difference in ligand electronegativity [22, 25]. As proposed above, the number of Ca–O–
C groups in CSH increases during the IBU loading process, which leads to the decrease
of the crystal field (decrease in the intensities of a1/a2 and b1/b2).
Figure 4-8(d) shows the comparison of Si K-edge XANES spectra of the CSH
mesoporous microspheres before and after IBU loading. Interestingly, before IBU
loading, the main peak “a” is relatively broad; this is due to the differences in chemical
environment at Si (IV) sites in the presence of Ca2+. However, after IBU loading, there is
a new peak “b” emerges at ~2 eV below the main peak and the main peak became sharper
and shifted about 0.5 eV toward higher energy. These observations are in excellent
agreement with our previous work (XANES collected on a large area of the specimen)
[41]. It is proposed that CSH forms some silanol groups (Si-OH) on the surface which
interacts with IBU (Scheme 4-2).

Scheme 4-2 Interaction between CSH and IBU at the Si local environment.
In the new structure (Si–O–C), due to the presence of the alkyl groups and the distortion
of silicate tetrahedron [46, 47]; we observe that the new peak b appears at lower photon
energy. On the other hand, most of the Si atoms of calcium silicate in the bulk are still in
a SiO4 tetrahedral environment and after drug loading, most of the silanol groups on the
surface could react with the carboxyl groups of IBU. As a result of this interaction, the
rest of Si atoms would be in a more “regular” SiO4 environment leading to that peak “a”
turns sharper and shifts to higher energy (the spectra are similar to that of SiO2 (Figure 49).
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Figure 4-9 XANES spectra comparisons of individual mesoporous CSH microsphere
before/after IBU loading and SiO2.
Figure 4-8(e) shows the XANES spectra comparison at O K-edge. First, the pre-edge
peak “a” shifts from 531.2 eV (due to the Ca–O crystal field effects) to 531.9 eV, which
is assigned to the transition from O 1s to π* states (O–C=O, from IBU) [27-29]; second,
the main resonance “b” exhibits splitting into a doublet. When we compare the XANES
of CSH loaded with IBU and silicon dioxide (black profile), one can see that the first
peak of main resonance of CSH loaded with IBU is similar to that of SiO2; the Si atoms
are in a tetrahedral SiO4 environment. Based on these observations, we can conclude that
the O K-edge XANES spectra of CSH after IBU loading exhibit the chemical
characteristics of both CSH and IBU. Besides, the O K-edge results are supplementary to
the proposed interactions deduced from the Ca L3,2-edge and Si K-edge XANES.

4.3.4

Thickness Mapping of Individual CSH Microsphere Before
and After IBU Loading

Since STXM can determine the absolute thickness of the sample, which means that
saturation does not occur, thickness distribution maps of the CSH microsphere before and
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after IBU loading at the Si K-edge and C K-edge can be obtained. The thickness was
obtained from stack fitting with the quantitatively scaled reference spectra of 1 nm
thickness. Silicon and carbon reference spectra were obtained by fitting the original
XANES spectra to match its calculated elemental linear X-ray absorption profile: calcium
silicate (CaSiO3: density = 2.900 g/cm3, and thickness = 1 nm, ibuprofen (C12H18O2:
density = 1.030 g/cm3, and thickness = 1 nm) in the pre-edge and continuum ((Figure 410).
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Figure 4-10 Reference spectra and elemental linear X-ray absorption profiles of
CSH and IBU. (a) and (b) CSH Si K-edge before and after IBU loading (black
profile: optical density spectrum of 1 nm thickness based on formula CaSiO3; red
profile: elemental linear X-ray absorption profile); (c) IBU C K-edge (black profile:
optical density spectrum of 1 nm thickness based on formula C12H18O2; red profile:
elemental linear X-ray absorption profile).
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Figure 4-11 shows the Si thickness map of single CSH microsphere before IBU loading.
The stripes across the microsphere, which are due to the beam vibration during the
STXM measurement, are not real structures of individual CSH microsphere. The
thickness of the condensed core of the CSH microsphere is determined to be about 235
nm, while the thickness of the outer surface area is around 24 nm (± 10 %). This result
confirms that under the ultrasonic irradiation, the CSH first forms a condensed core by
stacking up nanosheets as building blocks, then more nanosheets aggregate and selfassemble to bird’s nest like 3D hierarchical networks with mesopores and macropores
[20].

Figure 4-11 Thickness distribution of individual CSH microsphere at the Si K-edge;
the vertical color bar illustrates the thickness of the microsphere.
The thickness distribution maps of the CSH microsphere after IBU loading at Si K-edge
and C K-edge are shown in Figure 4-12(a) and (b), respectively. After drug loading, the
material thickness of the centre areas of CSH microsphere is equivalent to ~160 nm (±
10%) of crystalline CSH and that of the surface is around 18 nm (± 10 %). This thickness
of CSH derived from the absorption is smaller than the actual size of the microspheres in
TEM (~ 1 µm), which is due to the highly porous structure of the microspheres [20].
Besides, the thickness distribution map of IBU (Figure 4-12(b)) is more interesting and
significant because the carbon signal is only from IBU molecules and it illustrates the
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distribution of the drug molecules loaded in the drug carriers (and how much drug
molecules can be loaded into the drug carriers by quantitatively comparing the thickness
of CSH and IBU). The thickness ratios of CSH to IBU in the thick and thin regions are
given in Table 4-2.
Table 4-2 Thickness and thickness ratio of CSH to IBU in different regions*
.

Thickness (nm) Ratio
Si Map C Map Si/C
Region 1 (Red)
160
26
6.15
Region 2 (Green)
102
17
6.00
Region 3 (Purple)
18
3
6.00
*There is ± 10% thickness deviation according to Figure 4-12.

IBU were observed on the entire CSH microspheres, and they are more abundant in thick
areas (IBU thickness: ~ 26 nm) as compared to the outer surface (IBU thickness is around
2-3 nm); however thickness ratio of Si to C (also representing the thickness ratio of CSH
to IBU) remains the same in different regions, which suggests that IBU molecules were
uniformly loaded in the mesoporous CSH microspheres.
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Figure 4-12 Thickness distribution maps of an individual CSH microsphere after
IBU loading at (a) the Si K-edge and (b) the C K-edge. The vertical bar illustrates
the color code of the material thickness.

4.4 Conclusions
In summary, we have reported the chemical imaging (with thickness distribution) and
interactions between individual CSH microsphere and IBU on an individual mesomicrosphere using STXM. Our results suggest that IBU interacts with both Ca-OH and
Si-OH groups via its carboxylic acid functional group; this observation confirms previous
analysis that based on a large collection of many individual CSH nanostructures in the
drug delivery system. We find that the drug loading process has no diverse effect on the
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integrity of IBU molecules. Moreover, it is of great interest and significance that one can
obtain the drug loading distribution in an individual mesoporous CSH microsphere; also,
IBU molecules are loaded homogenously into CSH drug carriers.
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Chapter 5

5

Tracking Drug Loading Capacities of Calcium Silicate
Hydrate Carrier Loaded with Various Drugs: A
Comparative X-ray Absorption Near Edge Structures
Study

5.1 Introduction
In recent years, the number of medications to treat musculoskeletal disorders such as
osteoporosis and osteoarthritis is growing [1]. Conventionally, treatments are either by
oral intake or injection, however, the efficiency for drug access to specific bone sites is
poor, especially for bone implants for regenerations [2]. Thus, research efforts on drug
delivery systems, one of the most promising applications for medical purposes, have
significantly increased in the past decades. Many types of materials, including organic
polymers, bioactive glasses, ceramics, and organic-inorganic composites, have been
tested so far for drug delivery [3-6]. More recently, calcium silicate hydrate (CSH), a
type of bioceramics cement, has gained growing attention for applications in bone tissue
[7-10]. CSH not only is able to incorporate high dosages of drug molecules, but it also
exhibits impressive bioactivity by transforming into hydroxyapatite in simulated body
fluid (SBF). More importantly, their stimulatory effect on osteogenic differentiation of
stem cells is quite satisfactory [11]. Till now, a wide range of drugs (antibiotics [12],
anticancer drug [13], anti-inflammatory drug [14] and proteins [15] etc.) have been
successfully loaded into bioceramics drug carriers. However, high drug loading capacities
is still one of the key issues in drug delivery systems, which are affected by the routes
and the stabilities of the drug loading in drug carriers [16]. Yang et al. [17] summarized
possible types of drug adsorption mechanisms in mesoporous silica, which are dependent
on two factors: one is the structure of the drug carriers, including pore size, surface area,
and pore volume; the other is the functional groups present in drug molecules [5, 6].
* A version of this chapter has been accepted by J. Phys. Chem. B 2015, 119, 10052–
10059. Reproduced by permission of The American Chemical Society. DOI:
10.1021/acs.jpcb.5b04115
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Similar to mesoporous silica, CSH possesses abundant silanol groups (Si-OH) on the
surface [18-20]. Additionally CSH has better bioactivities because of the incorporation of
Ca-O layers into SiO2 tetrahedra [21-23]. Wu et al. successfully incorporated various
types of drug and protein into CSH drug carriers [24, 25]; however, few studies
systematically focus on the drug incorporation mechanisms in calcium silicate hydrate.
In Chapter 3, we revealed the interaction between ibuprofen (IBU) and CSH drug carriers
with different morphologies with the help of XANES at the Ca and Si K-edge [26].
Herein, we further choose two more important drug compounds with their unique
functional groups (Scheme 5-1): alendronate sodium (ALN), a bisphosphonate that
inhibits bone resorption by osteoclasts [27]; and gentamicin sulfate (GS), a typical
antibiotic drug that is extremely effective in treating bone infections [28]. In this chapter,
a comparative XANES study of the interactions between the mesoporous spheres of CSH
(MS-CSH) and three different drug molecules is reported, together with their drug
loading capacities (DLCs) in MS-CSH, from which the relationship between DLCs and
drug-carrier interactions emerges. This comparative study demonstrates that XANES is a
versatile and powerful technique for tracking the effects of drug loading, and opens wider
opportunities for the mechanical study of various types of biomaterials on the molecular
level in drug delivery, drug release in the future. The findings provide theoretical
foresights and guidance into further surface modifications or functionalization of CSH
carriers to strengthen the interactions with drug molecules, and then enhance the drug
loading capacities, control the drug release kinetics. It should be of interest to a wide
readership in a variety of fields, such as materials engineering, biomaterials, drug
delivery, surface chemistry and spectroscopy.
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Scheme 5-1 Chemical structures of ibuprofen (IBU), alendronate sodium (ALN) and
gentamicin sulfate (GS).

5.2 Experimental
5.2.1

Preparation of Mesoporous Spheres of CSH (MS-CSH)

MS-CSH were prepared by the self-assembly of CSH nanosheets via a sonochemical
method [29]. 5 mL of a 4 M NaOH aqueous solution and 2 mL of tetraethyl orthosilicate
(TEOS) were added into 500 mL of 0.03 M Ca(NO3)2 aqueous solution under magnetic
stirring at room temperature. The resulting mixture was ultrasonically irradiated for 1
hour under ambient conditions using a high-intensity ultrasonic probe with the power of
200 W (Ti-horn, 27 kHz, Hangzhou Success, China) immersed directly in the solution.
The product was collected by centrifugation and washed with deionized water and
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absolute ethanol three times, respectively. Then, the powder was dried in air at 60 °C
overnight.

5.2.2

Ibuprofen (IBU), Alendronate Sodium (ALN), and Gentamicin
Sulfate (GS) Drug Incorporations into MS-CSH

Ibuprofen was purchased from Shanghai Yuanji Chemical Co., Ltd, alendronate sodium
was purchased from Huaian San Ming Chemical Co., Ltd., and gentamicin sulfate was
purchased from Wuhan Hezhong Chemical Co., Ltd. All the chemicals were used as
received without further purifications. IBU was dissolved in hexane solution, ALN or GS
was dissolved in deionized water, to make 3 types of drug solution with the same
concentration of 40 mg·mL-1. Then 1 g of as-synthesized MS-CSH powder was added
into a 50 mL of IBU hexane solution, 0.4 g of MS-CSH powder was added into 20 mL of
ALN aqueous solution, and 0.2 g MS-CSH was added into 10 mL of GS aqueous solution
at room temperature, respectively. The flasks were immediately sealed, and the three
mixtures were treated ultrasonically for 2 minutes. The three containers were oscillated at
a constant rate of 160 rpm at 37 °C for 24 hours. After that the products were separated
by centrifugation, washed with hexane or deionized water, respectively, and dried in air
at 60 °C overnight.

5.2.3

Characterizations

The morphologies of MS-CSH before/after IBU, ALN, and GS loading were obtained by
TEM (Philips CM-10 TEM). FTIR spectra of drug carriers before/after different drug
loading were obtained on a FTIR spectrometer (Lambda FTIR-7600, Australia), and the
loading capacities of the three drugs in MS-CSH were determined on a STA 409/PC
simultaneous thermal analyzer (Netzsch, Germany) with a heating rate of 10 °C min−1 in
blowing air (via thermogravimetric (TG) curves).

5.2.4

XANES Measurements

XANES measurements were conducted at the Canadian Light Source (CLS) using the
Soft X-ray Microcharacterization Beamline (SXRMB), which is equipped with a double
crystal monochromator with two sets of interchangeable crystals operating with an
energy range of 1.7 to 10 keV. The InSb (111) crystals were used for the Si K-edge
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XANES measurements while the Si (111) crystals were used for the Ca K-edge XANES.
The integrity of drug molecules (against radiation damage) was tested by fast XANES
scans at the C K-edge with reduced beam dwell time (120 seconds for each fast XANES
measurement) at the high resolution Spherical Grating Monochromator (SGM) beamline
with an energy range of 250-2000 eV. At SGM beamline in the Canadian Light Source,
the flux is about 1012 photons/s; under the slit size of 20 µm, the beam dose on the
samples per area after 120 seconds fast scan is around 3x1011 photons/ µm2. The
detection modes are total electron yield (TEY) and X-ray fluorescence yield (FLY)
recorded with a Si drift solid state detector, tracking with surface and bulk sensitivities,
respectively. XANES data were analyzed using the Athena XAS analysis software
(http://cars9.uchicago.edu/ifeffit/Ifeffit), which is an interactive program for XAFS (Xray absorption fine structure) analysis (spectral background removal, normalization, and
linear combination fitting (LCF)).

5.2.5

FEFF Calculation

The modelling of crystal structure of CSH (Ca3Si2O7) has been verified and reported in
Chapter 3 and our previous publications [26, 29], and it has space group symmetry of
𝑃21 /𝑎 with lattice constant of a=10.557Å, b=8.885Å, and c= 7.858Å, α=90°, ß=119.586°,
γ=90°. The locations of the atoms in Ca3Si2O7 are listed in Table 5-1.
Table 5-1 Atomic coordinates of rankinite.
Site
Ca1
Ca2
Ca3
Si1
Si2
O1
O2
O3
O4
O5
O6
O7

x
0.0071
0.1677
0.3403
0.2948
0.0903
0.3579
0.1782
0.4105
0.2007
0.0970
0.1451
0.9299

y
0.0552
0.5745
0.9034
0.2357
0.2145
0.4038
0.2344
0.1016
0.1629
0.3857
0.1487
0.1536

z
0.2893
0.2083
0.2839
0.4314
0.9843
0.4229
0.5033
0.5523
0.2120
0.9810
0.8437
0.9394
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The XANES (X-ray absorption near edge structure) spectra of the cluster of the Ca3Si2O7
compounds with this crystal model are calculated by the multiple scattering theory using
the FEFF9 code [30]. This theory is based on the real-space Green’s function approach
[31].

5.3 Results and Discussion
5.3.1

Morphologies of MS-CSH Loaded with Different Drug
Molecules

The morphologies of mesoporous spheres of CSH before and after drug loading are
shown in Figure 5-1. CSH spheres with diameter around 1 µm are formed by the selfassembly of nanosheets (Figure 5-1(a)) [29]. After the loading of IBU, ALN, and GS
drugs, it should be noted that the general microsphere shape remains. However, the
contrast of CSH microspheres changed to some extent (Figure 1(b) to 1(d)), which is due
to the drug incorporation, leading to the increase in the thickness of CSH microspheres.
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Figure 5-1 TEM images of CSH before/after drug loading: (a) mesoporous spheres
of CSH (MS-CSH); (b) MS-CSH-IBU; (c) MS-CSH-ALN; (d) MS-CSH-GS; contrast
change means the thickness increase of CSH microspheres, indicating the drug
incorporations (scale bar = 500 nm).

5.3.2

Stabilities of Drug Molecules under the Collimated X-ray
Beam

We have shown that IBU is stable under the collimated beam in Chapter 4 [32]. In order
to examine the possibility of noticeable radiation damage of the ALN and GS drug
molecules, fast XANES scan tests at the C K-edge (120 seconds for each fast scan
spectrum measurement, the time of normal XANES collection is around 15 minutes)
were performed, as shown in Figure 5-2(a). It is apparent from Figure 5-2(a) that there
are no noticeable spectral changes observed for ALN and GS drug molecules after the
exposure to the X-ray beam, indicating that the structures of ALN and GS are stable
under the collimated X-ray beam. In order to confirm the integrity of the three types of
drug molecules after their loading, Figure 5-2(b) compares the XANES spectra before
and after drug loading at the C K-edge. There are several distinct spectral features need to
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mention: For CSH alone, the peak (a) at 290.3 eV is the “fingerprint” feature of CO2,
which is normal to see when CSH is stored in the atmosphere for a long time; peak (b) at
285.2 eV is related to the C 1s-π* transition from aryl ring of ibuprofen; the peak at 288.5
eV (c) is from the 1s-π* (C=O) of carboxylic acid as in the case of IBU. The peaks at
around 289 eV (d and e) is from C 1s-σ* (C-OH/C-NH2) of ALN and GS drug molecules
[33-36]. From the spectral comparisons at the C K-edge before and after the loading of
various drug molecules, there are no noticeable changes to the above spectral features
which are directly related to the functional groups of different drug molecules. Hence, it
indicates that the structures of three drugs are intact after drug loading.
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Figure 5-2 (a) Fast scan XANES spectra of ALN and GS drug molecules at the C Kedge (spectra were obtained sequentially), and (b) C K-edge XANES comparisons
before and after the loading of IBU, ALN and GS into CSH mesoporous
microspheres (feature “a” at 290.3 eV is for CO2 adsorption in CSH; “b” at 285.2
eV is the feature of aryl ring of IBU; “c” at 288.5 eV is 1s- π* transition from
carboxylic acid as in the case of IBU; “d” and “e” at around 289 eV is from C 1s-σ*
(C-OH/C-NH2) of ALN and GS drug molecules, respectively).
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5.3.3

Studies of Interactions between MS-CSH and Different Drug
Molecules by XANES

Before we compare the interactions between different drug molecules and CSH, we recall
the crystal structure of CSH; CSH has a layered structure, shown in Figure 5-3.

Figure 5-3 Crystal structure of CSH (green, beige and red dots represent for Ca, Si
and O atoms, respectively; α=900, β=119.5860, and γ=900).
It contains silicate “dreierkette” linear chains, in which every two of three silicate
tetrahetra share two oxygen atoms with central Ca ions, and we call the central part Ca-O
structure Ca-O layer. These layers are separated by an intermediate layer where water,
excess Ca2+, OH- and other ions are inserted to balance the charge [18-20, 37, 38]. In this
chapter, only the TEY spectra were shown because both TEY and FLY are very similar,
suggesting these samples are homogeneous (Figure 5-4). XANES spectra comparisons of
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different drug-CSH delivery systems at the Ca K-edge were shown in Figure 5-5 to
illustrate the carrier-drug interactions.

Figure 5-4 Comparisons of Ca K-edge TEY and FY XANES spectra of MS-CSH
loaded with different drug molecules.
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Figure 5-5 Ca K-edge total electron yield (TEY) XANES spectra (a) and linear
combination fitting (b to d) of MS-CSH loaded with IBU, ALN and GS.
Figure 5-5(a) shows the Ca K-edge XANES of MS-CSH before and after loading of three
types of drug molecules. There are four discernible XANES features, labelled “a”, “b”,
“c”, and “d” with increasing photon energy. The pre-edge peak (feature “a”) can be
ascribed to Ca 1s → 3d transition; the shoulder “b” is assigned to the 1s → 4s transition.
Although they are dipole forbidden, both features “a” and “b” can be still observed
because of the hybridization of Ca with ligand states of np-character. The most intense
peak (feature “c”) is due to Ca 1s → 4p dipole transition. The shoulder after the main
resonance (feature “d”) is mainly from multiple scattering processes [39-41]. By
comparing with the spectrum of MS-CSH (black), the differences from the features of b
and c in the CSH-IBU (red), CSH-ALN (blue) and CSH-GS (dark cyan) spectra can be
observed (more noticeable from the comparisons in the first derivative spectra at the Ca
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K-edge in Figure 5-6), showing the change of the Ca local structures by the interaction
between different drug molecules and Ca-OH groups. Based on the functional groups of
different drug molecules, XANES spectra of standard samples (calcium acetate
(Ca(C2H3O2)2), calcium phosphate (Ca3(PO4)2), and calcium sulfate (CaSO4)) were also
recorded (Figure 5-6), and a linear combination fitting (LCF) (Figure 5-5(b) to 5-5(d))
were analyzed by Athena software, and the results are listed in Table 5-2.
Table 5-2 Ca K-edge linear combination fitting results of MS-CSH loaded with IBU,
ALN and GS drug.
Percentage (%)
CSH Ca(C2H3O2)2 Ca3(PO4)2 CaSO4 R-factor
CSH-IBU
31
69
0.001430
CSH-ALN 41
59
0.002171
CSH-GS
29
71
0.001805
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Figure 5-6 XANES (a, c, e) and their first derivative (b, d, f) spectra comparisons of
MS-CSH before, after loaded with ibuprofen (IBU), alendronate sodium (ALN) and
gentamicin sulfate (GS) and relative standard samples.
From both LCF results and XANES spectra comparisons (Figure 5-6), we can infer that
the Ca K-edge XANES spectra of CSH-IBU, CSH-ALN and CSH-GS are more similar to
those of calcium acetate, phosphate and sulfate, respectively, indicating significant
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changes of the local environment of Ca occurred after drug loading. Because CSH
microspheres are three-dimensional network structures assembled by tiny CSH
nanosheets, it is highly possible that there are many Si-OH and Ca-OH groups ending on
the surface of nanosheets as the building blocks throughout the network of CSH carriers.
Thus, we conclude that IBU, ALN and GS molecules are linked to Ca-OH groups by
primarily electrostatic interactions; more specifically via the interactions between
carboxylic acid groups, phosphonic acid groups and sulfuric acid groups, respectively
(Scheme 5-2).

Scheme 5-2 Electrostatic interactions between Ca-OH groups and different drug
molecules.
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In Figure 5-7(a) (Si K-edge), before drug loading, there is only one broad peak (labelled
“a”, black), which is due to the Si 1s to 3p transition [40, 42], while IBU, ALN and GS
drug loadings lead to significant changes to the local structure of silicate. First, the width
of main resonance became narrower and the peak shifted to higher energy (~0.5 eV).
Second, a noticeable new feature (labelled “b”) was evolved, which is observed in TEY
spectra and absent in the FLY. These observations indicate that strong interactions
between different functional groups of drug molecules and silicate layers mostly took
place on the surface of MS-CSH.
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Figure 5-7 Si K-edge total electron yield (TEY) (a) fluorescence yield (FLY) (b)
XANES spectra of MS-CSH and MS-CSH loaded with different types of drug
molecules.
Silanol groups (Si-OH) on the surface provide the active sites for the interactions
between MS-CSH drug carrier and different drug molecules (Scheme 5-3). Compared
with the original silicate structure, the introduction of new drug molecules induces the
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distortion of the silicate tetrahedron on the surface [43-45]; hence a new peak “b”
emerged at the lower photon energy range only from TEY spectra. However, most of
silicates in the bulk of MS-CSH are still in the tetrahedral environment after drug
loading. Besides, MS-CSH in our study has a higher Ca/Si ratio (Ca/Si=1.5) [26, 29],
leading to a higher concentration of Ca-OH groups on the surface or in the interlayer,
relative to Si-OH groups (Figure 5-3) [19, 20, 38]. Hence, the electrostatic interactions
more likely take place between Ca and drug molecules (due to the higher Ca-OH
concentration and activity of Ca-OH, Si-OH to carboxylic acid), making silicate chains
“isolated”; more like the regular “SiO4” tetrahedral environment, hence the main
resonances at the Si K-edge TEY and FY are similar to that of SiO2 (Figure 5-7(a), sharp
peak, located at higher photon energy).

Scheme 5-3 Electrostatic interactions between silanol groups and different drug
molecules on the surface.
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5.3.4

Studies of Interactions between MS-CSH and Different Drug
Molecules by FTIR Spectroscopy

To further provide evidence for the existence of the interactions between different drug
molecules and MS-CSH, FTIR spectra of the MS-CSH before and after loading with
different drug molecules were obtained, as shown in Figure 5-8. For the MS-CSH, the
absorption around 970 cm-1 is attributed to the of Si-O stretching vibration of silicate.
Similar to the case of XANES analysis, several changes are apparent. First, after IBU
loading, the characteristic peak of C=O of IBU shifted from 1720 cm-1 to 1560 cm-1,
which is attributed to the polarity changes of –COOH group (linked to CSH). Besides, the
Si-O stretching is blue shifted, which is ascribed to polarity change of Si-O-Si (formation
of Si-O-C, magenta arrows) [26, 29, 46]. Second, the characteristic absorption peaks of
pure ALN molecules at 1020 cm-1 and 1050 cm-1 (P=O stretching vibration, indicated by
the navy arrows) are present [47], and after ALN loading, new absorption peaks were
observed at 961 cm-1 and 1084 cm-1 (in cyan arrows), which are assigned to P-O
stretching (PO43-) [48]. Third, major absorption peaks of pure GS were at 619 cm-1 and
~1100 cm-1 (dark cyan arrows) [49], and compared with the CSH FTIR spectrum (black),
a new broad peak was observed at ~ 1115 cm-1 (green), which belongs to the bands of
sulfate ions. All these observations are in a good agreement with the XANES results
discussed above; however, only parts of interactions can be confirmed because of the
overlapping of absorption bands.
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Figure 5-8 FTIR spectra of CSH mesoporous microspheres before and after loading
of different drug molecules, and pure IBU, ALN, GS are also shown for
comparisons (magenta arrows: Si-O-C stretching; navy arrow: P=O stretching
vibration; cyan arrows: P-O stretching; dark cyan arrows: major representative
absorption peaks of pure GS; green arrow: bands of sulfate ions).

5.3.5

Relationship between Drug Loading Capacities and
Interactions of CSH and Different Drug Molecules

In order to compare the drug loading capacities (DLCs) of MS-CSH for the three types of
drugs, thermogravimetric (TG) analysis of MS-CSH has been carried out as shown in
Figure 5-9. A two-level step profiles were observed from different drug loading systems
(IBU, ALN and GS). The first step occurring at around 80-180 °C is from the evaporation
of water and the second step of weight loss is from the drug burning in air. The drug
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loading capacities (DLCs) and efficiencies of different drug delivery systems are listed in
Table 5-3. Compared with ALN and GS drug molecules, MS-CSH has an extremely high
drug loading capacity with IBU drug molecules.
Table 5-3 Drug loading capacities for MS-CSH drug delivery systems.
Drug Delivery System

CSH-IBU
MS-CSH-ALN
MS-CSH-GS

DLCs
Loading Efficiencies
(wt. %)[a]
(%)[b]
185.4
92.5
15.4
19.2
8.9
22.2

[a]

Drug Loading Capacities = mdrug/mCSH wt. %.
Loading Efficiencies: the ratio of loaded amount of drug to the initial amount of drug before
loading.
[b]

Figure 5-9 TG curves of MS-CSH and MS-CSH-Drug delivery systems (more
weight change observed after loading, more drugs are incorporated into CSH).
Since the sizes of the drug molecules are in the range of one nanometer [2, 27], the nature
of drug molecules (functional groups) must play a vital role in the drug loading
capacities. Hence, the interactions between drug molecules and drug carriers are crucial
for the enhancement of DLCs. According to the XANES analysis, only acidic functional
groups of the drug molecules can be linked to abundant Ca-OH and Si-OH groups of
CSH mesoporous microspheres by electrostatic interactions. It is interesting to note that
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IBU has the highest drug loading amounts compared with the other two drugs. Shankland
et al. [50] proved the existence of hydrogen-bonded dimers of IBU by single-crystal
pulsed neutron diffraction. Babonneau et al. [51] demonstrated high mobility of IBU
molecules, which allows the attachment of more IBU drug molecules by adsorption.
Moreover, the electrostatic interaction between Ca2+ ions from the CSH carrier and the
carboxylic acid groups from the IBU drug molecules is one main factor responsible for
high IBU drug loading capacity. The IBU adsorption capacity on the CSH carrier nearly
follows the stoichiometric ratio of Ca2+ ions from the CSH carrier and the –COOH
groups from the IBU drug molecules, as demonstrated in previous work [24].
On the other hand, MS-CSH has the lowest DLCs of GS which is caused by the strong
interactions to some extent; although sulfate ions were linked to the Ca-OH and Si-OH
groups in the aqueous solution, the alkyl part (gentamicin part) is not connected to the
MS-CSH and this interaction may prevent further GS drug attachment to the MS-CSH.
Besides, the gentamicin part may suffer from steric effect, which also hinders more GS
drug molecules attachment. As a result, GS drug molecules are only loaded into MS-CSH
by the physical adsorptions into the mesopores; leading to lowest DLCs than the other
two CSH-Drug systems.

5.4 Conclusions
In this chapter, the interactions between different functional groups from three different
drug molecules and MS-CSH have been studied by XANES and FTIR spectroscopy. The
conclusions are summarized in Table 5-4. MS-CSH provides active linkage sites for
acidic functional groups of drug molecules by electrostatic interactions; while they are
not sensitive to the other groups such as amino and hydroxyl groups. Hence this result
will provide some hints to scientists in drug delivery and materials fields: the acidic drug
molecules can be loaded into CSH easily with higher DLCs; while further surface
modifications of CSH such as with acidic groups on the surface, may provide further
incorporation of basic drug molecules into CSH via the interactions, and may provide
high DLCs and controlled drug release profiles. Besides, the ratio between Ca2+ ions
from the CSH carrier and the –COOH groups from the IBU drug molecules is one main
factor responsible for high IBU drug loading capacity.
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Table 5-4 Sensitivities of Ca-OH, Si-OH groups to different functional groups of
drug molecules.
Ca-OH Si-OH
Carboxylic acid (R-COOH) groups
+
+
Phosphonic acid groups
+
+
Amino (R-NH3) groups
R-OH groups
Sulfuric acid groups
+
+
“+” means functional groups will have an interaction with either Ca-OH or Si-OH; while
“-” means they will not.
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Chapter 6

6

Tracking the Transformations of Mesoporous
Microspheres of Calcium Silicate Hydrate in Nanoscale
upon Ibuprofen Release: An XANES and STXM Study

6.1 Introduction
Nanostructured bioceramics nanomaterials, such as calcium phosphate (Ca3(PO4)2, CaP)
and calcium silicate (CS), have been widely applied as implants for the restoration of
bone and tooth. The development of mesoporous bioceramics opens up new possibilities
for drug delivery and bone therapies [1]. Since the discovery of Bioglass© by Hench and
co-workers in 1971 [2], various kinds of silicates, and glasses have been investigated for
hard tissue repair and replacement. Recently, CS material was proved to be excellently
bioactive and a potential candidate for bone repair and therapies [3-9]. A common feature
for all bioactive CS is that they can bond to living bones by forming hydroxyapatite
(Ca10(PO4)6(OH)2, HAp) on their surface when they are immersed into simulated body
fluid (SBF) with ion concentrations similar to human blood plasma.
In previous studies, many characterization methods have been used in the study of the
transformation mechanisms from CS to HAp. Among them, X-ray diffraction (XRD),
infrared spectroscopy (IR), scanning electron microscopy (SEM), transmission electron
microscopy (TEM) and energy-dispersive X-ray spectrometry (EDX) are the most
common techniques to study the composition, structure and morphology of the products.

* A version of this chapter has been published in CrystEngCommun. 2015, 17, 4117 –
4124. Reproduced by permission of The Royal Society of Chemistry. DOI:
10.1039/C5CE00500K
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However, the mechanism of biomineralization of CS is still not completely clear: one
controversial issue is the presence of CaCO3; Siriphannon et al. [3] and Wan et al. [6]
reported that CaCO3 were present during the HAp formation; while Gou et al. [5]
reported that the final products would be carbonate-containing HAp; Li et al. [10]
reported the absence of CaCO3 after the in vitro test; the other problem is about the silicarich layer during biomineralization. Although it is well accepted that the silica-rich layer
provides favourable sites for HAp precipitation, there has been no direct evidence
showing the presence of silica-rich layer using the above mentioned conventional
techniques. X-ray absorption near edge structures (XANES) spectroscopy is an element
specific technique, which probes the electronic states intimately associated with the
absorbing atom in the vicinity of the X-ray absorption threshold (LUMO in molecules
and the conduction band in semiconductor for example via dipole transitions) [11].
XANES provides information on the oxidation state, coordination and symmetry of the
element of interest. Materials with different structures or compositions have their unique
XANES spectra at specific absorption edges (e. g.: calcium silicate hydrate (CSH),
amorphous calcium phosphate, HAp and CaCO3 show different XANES features at the
Ca K-edge), by which qualitative analysis is very reliable by “fingerprinting” [12-16].
Under favourable conditions (high quality data), quantitative information can be obtained
by fitting the XANES data to a linear combination of XANES of standard components.
Additionally, synchrotron source provides collimated and high photon flux that allows for
detecting the minor components (even less than 0.1 wt. % [17]) in materials no matter
they are crystalline, amorphous (XRD is only suitable for crystals) or in solution.
Scanning transmission X-ray microscopy (STXM) [18, 19] provides spectromicroscopic
information of nanomaterials; thus both electronic and spatial features of a single
nanostructure can be revealed at nanoscale (~30 nm). Therefore, the combination of
STXM and XANES can monitor the spectral change and image the transformation from
CSH to HAp at nanoscale simultaneously, hence affords a comprehensive understanding
of the biomineralization mechanism of CSH in connection with drug release.
Previous investigations reported the formation of HAp on CS in SBF without drug
loading [3-6, 10]. Few researches illustrated the bioactivity of bioactive glasses (BG) and
HAp when drug was released in SBF [20-22]. In this chapter, we investigated the drug
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(ibuprofen, IBU) release from mesorporous CSH microspheres and the biomineralization
of CSH during drug release in SBF using synchrotron based techniques (XANES and
STXM). This study provides new insights into the mechanism of CSH biomineralization.

6.2 Experimental
6.2.1

Preparation of Mesoporous CSH Microspheres

CSH mesoporous microspheres were prepared by the self-assembly of CSH nanosheets
via a sonochemical method [23]. 5 mL of a 4 M NaOH aqueous solution and 2 mL of
tetraethyl orthosilicate (TEOS) were added into 500 mL of 0.03 M Ca(NO3)2 aqueous
solution under magnetic stirring at room temperature. The resulting mixture was
ultrasonically irradiated for 1 hour under ambient conditions using a high-intensity
ultrasonic probe with the power of 200 W (Ti-horn, 27 kHz, Hangzhou Success, China)
immersed directly in the solution. The product powder was collected after centrifugation
and washed with deionised water and absolute ethanol three times, then dried in air at 60
°C overnight.

6.2.2

IBU Drug Loading

The as-synthesized powder (1.0 g of mesoporous CSH microspheres) was added into a 50
mL IBU hexane solution (~40 mg·mL-1) in a flask at room temperature. The flask was
immediately sealed to prevent hexane from evaporation, and the mixture was treated by
ultrasound for 2 minutes. Then the flask was oscillated at a constant rate of 160 rpm at 37
°C for 24 hours. After that the product was separated by centrifugation, washed with
hexane, and dried in air at 60 °C overnight.

6.2.3

In Vitro Test

To investigate the kinetics of IBU release from CSH microspheres and the
biomineralization of CSH and to mimic those processes in the human body, experiments
were carried out in a simulated body fluid (SBF). The ion concentrations of the SBF,
shown in Table 6-1, are similar to the physiological concentrations in the human blood
plasma [24]. The pH of the SBF solution was buffered at 7.40 ± 0.02 with 1 mol/L HCl
and tris-(hydroxymethyl)-aminomethane [(CH2OH)3CNH2]. 2 g of the as-synthesized
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CSH-IBU powder was split equally into 10 specimens (0.2 g each), and then each of
them was soaked in 200 mL of SBF solution at 36.5 °C for 1, 2, 3, 4, 5, 6, 12, 24, 36, 48
hours, respectively under constant shaking (120 rpm). A portion of the IBU-release
medium (2.0 mL) was extracted for UV-Vis absorption analysis (Techcomp, UV2300) at
the wavelength of 263 nm at given time intervals shown above. The solid products were
separated by centrifugation, rinsed with absolute ethanol, and dried in air at 60 °C
overnight for XRD, TEM and XANES studies.
Table 6-1 Ion concentrations of SBF and human blood plasma (mmol/L)
Ion
SBF Human Blood Plasma
+
Na
142.0
142.0
K+
5.0
5.0
+
Mg
1.5
1.5
Ca2+
2.5
2.5
Cl
147.8
103.8
2HCO3
4.2
27.0
HPO421.0
1.0

6.2.4

Characterization

The thermogravimetric (TG) curves were measured on a STA 409/PC simultaneous
thermal analyzer (Netzsch, Germany) with a heating rate of 10 °C min−1 in blowing air to
measure the drug loading capacities of mesoporous CSH microspheres. The
morphologies of the CSH microspheres before/after IBU loading, CSH-IBU
microspheres after IBU releasing in SBF for various time periods were obtained by TEM
(Philips CM-10 TEM). The compositions of biomineralization products for various time
periods were characterized by XRD (Rigaku D/max 2550 V, Cu Kα radiation, λ =
1.54178 Å). The concentrations of Ca, P and Si of the SBF after IBU releasing from CSH
were determined using an inductively coupled plasma (ICP) instrument (JY 2000–2,
Horiba, France).

6.2.5

XANES Measurements

XANES measurements were conducted at the Canadian Light Source (CLS) using the
Soft X-ray Microcharacterization Beamline (SXRMB), which is equipped with a double
crystal monochromator with two sets of interchangeable crystals operating with an
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energy range of 1.7 to 10 keV. The InSb (111) crystals were used for the Si K-edge
XANES measurements while the Si (111) crystals were used for the Ca K-edge and P Kedge XANES. The detection modes are total electron yield (TEY) and X-ray fluorescence
yield (FLY), tracking with surface and bulk sensitivities, respectively. XANES data were
analyzed using the Athena XAS analysis software
(http://cars9.uchicago.edu/ifeffit/Ifeffit), which is an interactive program for XAFS
analysis, combining high-quality and well-tested XAFS analysis algorithms, tools for
general data manipulation, and graphical display of data.

6.2.6

STXM Measurements

STXM measurement was conducted at the Soft X-ray Spectromicroscopy (SM) beamline
at the CLS; SM is equipped with a 25 nm outermost-zone zone plate (CXRO, Berkeley
Lab). The diffraction-limited spatial resolution for this zone plate is about 30 nm with a
spectral resolution of 0.05 eV at the C K-edge. Image sequence (stack) scans over a range
of photon energies were acquired for the same sample region at the C K-edge, Si K-edge
and P K-edge. STXM data were analyzed using the aXis2000 software package
(http://unicorn.chemistry.mcmaster.ca/aXis2000.html), which allows for detailed
interactive processing of the images and fitting the image stacks with the reference X-ray
absorption spectra. More details about STXM measurement and data analysis can be
found elsewhere [25, 26].

6.3 Results and Discussion
6.3.1

Morphologies of CSH Microspheres Before and After IBU
Loading

The morphologies of the mesoporous CSH microspheres before and after IBU loading
were reported in our previous studies and chapters (Figure 6-1) [23, 27, 28].
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Figure 6-1 TEM images of mesoporous CSH microspheres before (a) and after (b)
IBU loading.

6.3.2

IBU Loading Capacity of CSH Microspheres

To measure the drug loading capacity of CSH microspheres, the TG analysis of CSH and
CSH loaded with IBU were carried out. As shown in Figure 6-2, there is a two-level-step
profile for the weight loss of the CSH-IBU system; the weight losses at 80-100 °C and
280-480 °C originate from the evaporation of water and the clean burn of IBU in air,
respectively. The drug loading capacity (DLC) (mIBU/mCSH wt. %) of CSH microsphere is
calculated based on the TG curves, showing a high value of 180 wt. % (i.e. 1.80 g IBU is
loaded per gram of carriers), which agrees with our previous studies [23, 27].
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Figure 6-2 TG curves of mesoporous CSH microspheres and CSH loaded with IBU.

6.3.3

Morphologies Changes of CSH Microspheres in SBF upon
IBU Release

Figure 6-3 shows the micrographs of the CSH microspheres after soaking in the SBF
solutions for various time periods. In comparison with the microspheres before soaking,
most of the carriers remained intact after the samples were soaked in the SBF for 1 hour.
At 5 hours, some microspheres were broken down; sheets-like products can be found on
the edge of microspheres. After longer soaking time (24 hours and 48 hours),
microspheres can be barely observed, instead, most of the microspheres turned into the
aggregation of particles and flakes.
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Figure 6-3 TEM micrographs of CSH-IBU microspheres soaked in SBF solution for
different time: (a) 1 hours, (b) 5 hours, (c) 24 hours, and (d) 48 hours.

6.3.4

XRD Study of CSH Microspheres Phase Transformations in
SBF upon IBU Release

To determine the compositions of the products having immersed in SBF solution for
various period of time, XRD data of the CSH-IBU microspheres soaked in the SBF
solution for various time periods were obtained as shown in Figure 6-4. One can see that
starting from 4 h, the diffraction peaks (e.g. 2θ = 26° and 32° PDF number: 09-0432) of
HAp emerge clearly in the XRD patterns. On the contrary, in the first 3 h, although weak
crystalline CSH diffraction patterns can be still observed (2θ = 29° PDF number: 330306), a broad peak is more prominent, indicating that some amorphous components
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were formed, however, no further information can be revealed from XRD to illustrate the
compositions of amorphous specimens.

Figure 6-4 XRD patterns of CSH-IBU powder soaked in SBF solution for different
time.

6.3.5

XANES Study of CSH Microspheres Phase Transformations
in SBF upon IBU Release

In order to reveal the amorphous compositions of the products formed in the first several
hours, XANES measurements at the Ca K-edge, P K-edge and Si K-edge were conducted
(Figure 6-5). We only show TEY XANES for the discussions because both TEY and
FLY are similar since the specimens are homogeneous and optically thin and FLY shows
no detectable thickness effects.
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Figure 6-5 Ca (a), P (b) and Si (c) K-edge XANES spectra of CSH-IBU microspheres
soaked in SBF solution for various time.
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Figure 6-5(a) shows the Ca K-edge XANES of CSH-IBU microspheres after having been
immersed in the SBF solution for different periods of time. There are four discernible
XANES features, labelled as “a”, “b”, “c”, and “d” at increasing photon energy. The most
intense peak (feature “c”) is due to Ca 1s → 4p transition. The pre-edge peak (feature
“a”) can be ascribed to 1s → 3d transition; the shoulder “b” is assigned to the 1s → 4s
transition, both of which can be observed are due to the hybridization of Ca with ligand
states of np-character, leading to the departure from perfect crystal symmetry [29]. The
shoulder after the main resonance (feature “d”) is mainly from multiple scattering
processes [30-32]. By comparing the spectra of CSH, amorphous calcium phosphate and
HAp standard samples, the main “fingerprint” differences between CSH and HAp clearly
identifiable are the white line “c” and feature “d”. Starting from the spectrum of 3 h (dark
cyan), the spectra are almost the same as that of HAp, indicating the formation of HAp on
the surface of mesoporous CSH microspheres. After a linear combination fitting
procedure using standard spectra of CSH, amorphous calcium phosphate, HAp and
CaCO3 (Figure 6-6), the compositions of amorphous samples in the first 4 hours can be
clearly revealed, as shown in Table 6-2.
Table 6-2 Ca K-edge linear combination fitting results of samples after soaked in
SBF solution in the first 4 hours.
Percentage (%)
CSH CaCO3 Amorphous CaP HAp R-factor
1 hour
8
6
13
73
0.00298
2 hour
3
11
9
77 0.000984
3 hour
0
7
1
92 0.000809
4 hour
0
0
0
100 0.000864
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Figure 6-6 Comparison of Ca K-edge XANES spectra and linear combination
fitting in the first 4 hours.
Combined with the results from XRD, we find that the dominant composition is
amorphous HAp at the early stage of drug release, of which the percentage increase until
the spectrum of 4 h which is identical to that of HAp, and it gradually becomes
crystalline. Moreover, from the first several spectra, the contribution of amorphous
CaCO3 and calcium phosphate can also be observed, indicating that amorphous calcium
phosphate was first formed then transformed into amorphous HAp rapidly, which is due
to the stability of amorphous calcium phosphate in aqueous media: HAp has a lower
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solubility in water than other form of calcium phosphate, and CaCO3 was formed during
the biomineralization.
The P K-edge XANES spectra also provide direct evidence for the formation of HAp. As
seen in Figure 6-5(b), there is no P signal before the samples were immersed in the SBF
solution (the curve labelled as 0 h); while a strong P signal was detected after the powder
was soaked in the SBF for 1 h. The principal peak “a” results from P 1s → 3p transitions.
For the HAp minerals, there exhibits a distinctive post-edge shoulder “b” and higherenergy peaks at around 2163 eV (“c”) and 2170 eV (“d”) [15, 31, 33]. For the first 2 h,
features b, c and d are less apparent, which are mixed with some amorphous Ca3(PO4)2.
While all of the features are similar to those of HAp after the CSH-IBU microspheres
were soaked in the SBF solution for more than 3 h. The result of linear combination
fitting at the P K-edge (Figure 6-7 and Table 6-3) is consistent with the Ca K-edge
results.
Table 6-3 P K-edge linear combination fitting results of samples after soaked in SBF
solution in the first 3 hours.
Percentage (%)
Amorphous CaP HAp R-factor
1 hour
22
78 0.006551
2 hour
6
94 0.005300
3 hour
1
99 0.004686
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Figure 6-7 Comparison of P K-edge XANES spectra and linear combination fitting
in the first 3 hours.
The observation at the Si K-edge is interesting (Figure 6-5(c)). During the IBU release
process, there is only one prominent peak (labelled as “a”) in the Si K-edge XANES
spectra, which is identified as the Si 1s to 3p transition for silicon (IV) in a tetrahedral
oxygen ligand environment [31, 34]. Comparing to the spectrum of the CSH-IBU before
IBU release (0 h), the peak at lower photon energy labelled as “b”, is due to the
interaction between silanol groups (Si-OH) and carboxylic acid groups of IBU [27, 28]
(less prominent in the FLY spectra, 0 h in Figure 6-8); it disappears nearly entirely in the
spectra of CSH-IBU after IBU release. The disappearance of this peak once CSH-IBU
microspheres were immersed in the SBF is likely due to the fast release of IBU from
CSH carriers into SBF, resulting in the rapid decrease of the interaction between IBU and
CSH. Compared to the standard sample SiO2, the spectra of CSH-IBU microspheres after
IBU release for different time periods are all identical to that of SiO2, indicating that
some mesoporous CSH microspheres have been hydrolyzed into SiO2 during IBU release
[35, 36]. Interestingly, the feature “b” can be detected again in the Si K-edge TEY spectra
after 6 hours release although the intensities are much weaker than before (0 h spectrum).
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Figure 6-8 Si K-edge FLY XANES spectra of CSH-IBU microspheres soaked in SBF
solution for various time periods.
The IBU release profile of mesoporous CSH microspheres in SBF is shown in Figure 6-9.
Initially, there was a burst release effect at the early stage; about 85 % IBU were released
in the first hour, and 97-98 % of loaded IBU were released after 4 hours. This type of
release proﬁle is suitable for an acute infection or inﬂammation, when an immediate high
dosage is needed for a short period of time. Hence, according to the IBU release profile,
the reappearance of feature “b” at the Si K-edge after 6h can be ascribed to the readsorption of IBU on the surface of the release products (SiO2), since the equilibrium of
IBU release was reached during that period of time. Since no SiO2 phase was observed
from XRD, all the SiO2 components detected from XANES are amorphous.
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Figure 6-9 The cumulative IBU release of mesoporous CSH microspheres in SBF.

6.3.6

STXM Analysis of CSH-IBU System after Having Soaked in
SBF for Five Hours

Since it is shown that the CSH-IBU system starts to transform into crystalline HAp after
having been soaked in the SBF solution for more than 4 h, it would be desirable if we
could identify and map the compositions of the in vitro samples after biomineralization at
nanoscale. Figure 6-10(a) shows the STXM image of the CSH-IBU microspheres after
having been soaked in the SBF solution for 5 h. No microspheres could be observed
anymore; instead, an aggregation of flakes in several microns is seen. In order to monitor
the components of the biomineralization product in details, we first obtain C K-edge
XANES spectra isolated from 6 different regions of interest (ROIs) on the sample as
shown in Figure 6-10(b). All the ROIs were selected randomly based on the optical
densities (sample thickness) to illustrate the uniformity/heterogeneity of various
components at different edges. Since STXM is a powerful technique to study carbon
nanomaterials and provides high quality absorption spectra with submicron spatial
resolution [37-39], C K-edge XANES from different ROIs could reveal the presence of
residual IBU and carbon related compounds. From Figure 6-10(c), compared with the
spectrum of IBU powder (black profile), there is no significant change or beam damage
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to the residual IBU molecules on the drug release products: the sharp peak “a” located at
285 eV is from the carbon 1s to π* transition for the aryl rings of IBU molecules; the
peak “b” located at 288.3 eV is from the carbon 1s to π* transition for carboxylic
functional groups of IBU; the less apparent feature “c” became more prominent after
having been soaked in SBF for 5h, and slightly shifted to higher photon energy,
indicating the presence of carbonate ions [40-44].

Figure 6-10 (a) STXM optical density image of CSH-IBU sample soaked in SBF for
5h (averaged from 280 to 2190 eV); (b) ROIs taken from the CSH-IBU sample: Red:
ROI-1, Magenta: ROI-2, Orange: ROI-3, Green: ROI-4, Blue: ROI-5 and Cyan:
ROI-6; (c) XANES spectra taken from each ROI displayed in (b) at the C K-edge.
We have also compared the XANES spectra isolated from different ROIs at the Si Kedge (Figure 6-11(c)) and the P K-edge (Figure 6-11(d)); it is interesting to note that the
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strongest P signals were detected in ROI-1 and ROI-2 (red and magenta spectra of Figure
6-11(d)), where show the highest Si optical densities as well. Since STXM can determine
the absolute thickness of the sample, SiO2 and HAp thickness distributions are shown in
Figure 6-11(a) and (b), respectively.
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Figure 6-11 Thickness distribution maps of CSH-IBU sample soaked in SBF for 5h
at (a) the Si K-edge and (b) the P K-edge. The vertical bar illustrates the color code
of the material thickness; XANES spectra of CSH-IBU sample soaked in SBF for 5h
at the Si K-edge (c) and P K-edge (d) (ROI 1-6 are the same regions as shown in
Figure 6-10(b)).
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For STXM thickness modelling procedure, XANES spectra were obtained by converting
the signal to optical density (OD) based on Beer-Lambert Law:
𝐼
𝑂𝐷 = − ln( ) = 𝜇 ∙ 𝜌 ∙ 𝑡
𝐼0

(6 − 1)

where I0 and I are the incident and transmitted X-ray photon flux (photons), respectively.
μ is the energy dependent mass absorption coefficient (cm2/g), ρ is the density (g/cm3) of
the material, and t is the sample thickness (nm). Then these spectra were converted to
absolute linear absorbance scales (optical density per nm thickness sample). The
elemental linear X-ray absorption, which neglects interactions such as bonding among the
atoms, is calculated by aXis2000 using Equation (6-1) and (6-2):
𝜇=

𝑁A
∑ 𝑥𝑖 ·𝜎𝑎𝑖
MM

(6 − 2)

i

where NA is the Avogadro’s number, MM is the molecular weight of a compound
containing xi atoms of type i, σai is the atomic photo absorption cross section (cm2/atom)
for type i atom. Then, the thickness was obtained by comparing the OD of each pixel in a
STXM image and reference spectra. In this study, silicon and carbon reference spectra
were obtained by fitting the original XANES spectra to match its calculated elemental
linear X-ray absorption profile: hydroxyapatite (Ca5(PO4)3(OH): density = 3.160 g/cm3,
and thickness = 1 nm, silicon dioxide (SiO2: density = 2.650 g/cm3, and thickness = 1
nm) in the pre-edge and continuum. The thickness was obtained from stack fitting with
the quantitatively scaled reference spectra of 1 nm thickness (Figure 6-12).
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Figure 6-12 Reference spectra and elemental linear X-ray absorption profiles of
SiO2 (a) (black profile: optical density spectrum of 1 nm thickness based on formula
SiO2; red profile: elemental linear X-ray absorption profile) and HAp (b) (black
profile: optical density spectrum of 1 nm thickness based on formula
Ca5(PO4)3(OH); red profile: elemental linear X-ray absorption profile).
After 5 h in vitro test, most of the SiO2 were located in the top left area with the largest
thickness around 200 nm (± 10%). Moreover, one can see that from Figure 6-11(b), more
HAp can be detected around the red areas. The average SiO2, HAp thickness of selected
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areas is given in Table 6-4 (the areas are shown in circles with different colors in Figure
6-11(a) and (b)).
Table 6-4 Thickness of SiO2 and HAp in different regions.
Average Thickness [nm]
SiO2 Map HAp Map
Circle 1 (Red)
173
36
Circle 2 (Navy)
91
86
Circle 3 (White)
73
27
There is ± 10% thickness deviation according to Figure 6-11(a) and 11 (b).
It is interesting to note that area 2 (navy circle) and 3 (white circle) have the similar
thickness of SiO2; however, the thicknesses of HAp in those areas are quite different.
This is largely because area 2 is closer to area 1 (red circle) where most SiO2 are located.
During the biomineralization processes, some CSH microspheres (silanol abundant) [4547] partially broke down and some silicate hydrolyzed into SiO2 (area 1); this
aggregation provides preferred further nucleation site for the growth of HAp [10, 48, 49].
That explains why we observe more HAp in area 2 rather than area 3.

6.3.7

Changes of Ca, Si and P during the Biomineralization

Figure 6-13 shows the change in concentration of Ca, Si and P in the SBF solution
measured by ICP after soaking CSH-IBU microspheres in SBF for different time periods.
At early stages, the Si concentrations in SBF increased when the IBU was released from
CSH microspheres, indicating the dissolutions of CSH microspheres in the SBF solution.
Meanwhile, there was a steep decrease of P concentration in the first 6 h of soaking,
corresponding to the phosphate consumption in the SBF solution in order to form HAp on
the surface of CSH microspheres. It should be noted that there is also a rapid drop of Ca
concentrations in the first 6h of soaking and the concentration remained almost steady
after 1 day. This observation is different from the Ca change in the previous studies [3, 5,
6, 10]. The reason why the rate is different is that the Ca dissolution rate of CSH
microspheres is slower than the Ca precipitation rate from the SBF solution (the coprecipitation of Ca2+ and PO43- from the SBF solution to form HAp on the surface of drug
carriers).
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Figure 6-13 Concentration changes of Ca, P and Si after soaking CSH-IBU in SBF
for different period of time.

6.4 Conclusions
Finally, based on all the above results, the processes of drug release and CSH
biomineralization emerge. As illustrated in Figure 6-14, at the early stages of drug
release, crystalline CSH microspheres disassemble into amorphous flake-like sheets,
some silicate ions undergoes exchange into the SBF solution while others becomes
hydrolyzed into amorphous silica. Both Ca (from CSH and SBF) and PO43- ions (from
SBF) (Figure 6-13) first form amorphous calcium phosphate at first 2h, then quickly
transformed into amorphous HAp, and the finally products were crystalline HAp after the
samples were soaked in the SBF solution for more than 3h. At the same time, some
bicarbonate ions (HCO3-) co-precipitate from SBF, generating amorphous CaCO3.
Moreover, from STXM data, more P were detected around the area where more Si were
located; indicating the abundant silanol groups and the following hydrolyzed SiO2
provided preference aggregation sites of HAp.
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Figure 6-14 Illustration of the proposed mechanisms for the IBU (black dots) release
from mesoporous CSH microspheres and biomineralization.
In this chapter we have illustrated that mesoporous CSH microspheres have very large
drug loading capacities, which can reach as high as 1.80 g/g. The CSH-IBU system has a
rapid drug release profile, which is suitable for acute disease (need of high drug dosage in
a short period of time). The biomineralization mechanism for mesoporous CSH
microspheres loaded with IBU in the SBF solution was elucidated via XANES and
STXM. What’s more important, we have demonstrated that synchrotron radiation is a
very sensitive and powerful technique to study bioceramics: XANES has the ability to
identify the chemical form of products (Si, P and Ca K-edge) even they are amorphous
state. Using the highly-collimated STXM beam (best resolution: 30 nm), we provided
spatial evidence of biomineralization formation (Si and P particularly).
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Chapter 7

7

Effects of Polymers on the Drug Loading Capacities
and Drug Release of Calcium Silicate Hydrates: An Xray Absorption Near Edge Structures (XANES) Study

7.1 Introduction
Calcium silicate hydrate (CSH) has served as the component of glass or cement concrete
for a long time; moreover, it was found to be an excellent candidate for bioceramics in
bone regeneration and augmentation in recent two decades because of their impressive
bioactivity, biocompatibility and biodegradability [1-4]. Furthermore, its stimulatory
effect on osteogenic differentiation of stem cells makes CSH a new type of promising
biomaterials in biomedical applications [5-7]. Currently, composite biomaterials
comprising inorganic bioceramics and organic polymers are even more attractive because
their combination improves their mechanical properties and stabilities, and further
enhances tissue interaction [8]. With increasing demands for biomaterials to deliver drugs
to local hard-tissue site in order to increase the effectiveness of therapy, efforts have been
invested in developing composite biomaterials with a drug-delivery capacity [9-12].
However, high drug loading capacities and controlled drug release profiles are still key
challenges in drug delivery systems, which are affected by both structures of drug
carriers, including pore size, pore volume and surface areas, etc., and interactions
between drug carriers and drug molecules[13-15].
Previously, a variety of analytical techniques such as X-ray photoelectron spectroscopy
(XPS) [16], nuclear magnetic resonance (NMR) [17] and Fourier transform infrared
(FTIR) spectroscopy [18] have been applied in the structural investigation of
heterogeneous cement materials. More recently, X-ray absorption spectroscopy (XAS)
has also been used to study cement paste [19]. X-ray absorption near edge structure
(XANES), a near edge region of the XAS (generally from 20 eV below to 50 eV above
the absorption edge), is an elemental specific technique, because the binding energy of
each core electron of each element is unique. XANES provides information about
immediate surroundings of the absorbing atom and it is sensitive to the oxidation state,
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local symmetry of elements of interest [20]. Hence, we not only can investigate the
structure of the drug carriers CSH before and after polymer incorporation, but also track
the interactions between drug molecules and CSH/polymer composites by the XANES
spectral comparisons at different elements/edges; thus, we gain a comprehensive
understanding of how polymers and drug molecules interact with different functional
groups (calcium and silicate in this case) of drug carriers and deduce their drug loading
capacities and release profiles.
Recently, Ha et al. investigated polymers on the structure and the carbonation of CSH
using scanning transmission X-ray microscopy [19]; however, the use of X-ray
absorption near-edge structure (XANES) to study CSH/polymers composites as drug
carriers in drug delivery systems has yet to be reported. Herein, we report a controlled
precipitation synthesis of CSH nanosheets, followed by a room-temperature solution
preparation of three CSH/block copolymer composites by the incorporation of one each
of the three different block copolymers: polyvinyl alcohol (PVA), monomethoxy
(polyethyleneglycol)-block-poly(DL-lactide-co-glycolide) (mPEG-PLGA) and
poly(diallyldimethylammonium chloride) (PDDA). Ibuprofen (IBU), a typical antiinflammatory drug is further employed for the investigations of drug loading and release
properties of these polymer incorporated composites (Scheme 7-1). XANES is utilized to
study the structural change of CSH after the formation of CSH/polymer composite and
the interactions between IBU and CSH/polymer composite to reveal the effects of
polymer incorporation on drug loading capacities and drug release kinetics.
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Scheme 7-1 Chemical structures of different polymers and ibuprofen.

7.2 Experimental
7.2.1

Materials

Na2SiO3∙9H2O, Ca(NO3)2∙4H2O, NH3∙H2O, polyvinyl alcohol (PVA, Mw = 1750±50 )
were purchased from Sinopharm Chemical Reagent Co., Ltd. Monomethoxy
(polyethyleneglycol)-block-poly(DL-lactide-co-glycolide) (mPEG-PLGA, Mw = 8000;
the molecular weight of the mPEG segment was 5000 and the molar ratio of DL-lactide
to glycolide was 75:25.) was purchased from Jinan Daigang Biomaterial Co., Ltd.
Poly(diallyldimethylammonium chloride) (PDDA, Mw 100,000-200,000, 20 wt. % in
H2O) was purchased from Sigma-Aldrich. Ibuprofen (IBU) was purchased from Shanghai
Yuanji Chemical Co., Ltd. The phosphate buffer saline (PBS, pH = 7.4 at 37 °C) was
purchased from Bio Basic Inc. All the purchased chemicals were used as received
without further purification.
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7.2.2

Preparation of CSH/polymer Composites

Calcium silicate hydrate nanosheets were prepared by a reaction rate-controlled solution
precipitation method [21]. For the preparation of CSH/polymer composites, solution A
was prepared by dissolving 0.853 g of Na2SiO3∙9H2O into 50 mL of deionized water, into
which 5 mL of 0.6 M Ca(NO3)2 aqueous solution was injected at a constant rate of 2.5
mL∙ h-1 under magnetic stirring for 3 hours followed by addition of 1 mL of aqueous
ammonia (~27%). Solution B was 10 mL of a 10% PDDA aqueous solution; Solution C
and D were prepared by dissolving 0.5 g of mPEG-PLGA into 10 mL of deionized water
and 1 g of PVA into 10 mL of deionized water, respectively. Then 25 mL each of
solution A was added into solution B, C and D, under magnetic stirring for 8 days. The
CSH/polymer composites were collected by centrifugation, washed with deionized water
three times and absolute ethanol once, then dried at 60 °C.

7.2.3

IBU Drug Loading and In Vitro Release

0.035 g of CSH/PVA, 0.1 g of CSH/mPEG-PLGA and 0.02 g CSH/PDDA as synthesized
composites were added into 1.75 mL, 5 mL, and 1 mL of IBU hexane solution (40
mg·mL-1) in three different flasks at room temperature, respectively. The flask was
immediately sealed to prevent hexane from evaporation, and the mixture was treated by
ultrasound for 2 minutes. Then the flask was oscillated at a constant rate of 160 rpm at 37
°C for 24 hours. After that the product was separated by centrifugation, washed with
hexane once, and dried in air at 60 °C. Then each (20 mg) of the as-prepared IBU-loaded
composites were immersed in a 40 mL phosphate buffered saline (PBS) at 37 °C under
shaking at a constant rate. The IBU release medium (2.0 mL) was extracted for UV-Vis
analysis at the wavelength of 263 nm at given time intervals.

7.2.4

Characterization

The transmission electron microscopy micrographs were obtained with a transmission
electron microscope (TEM, Philips CM-10) at Biotron Lab, University of Western
Ontario. The thermogravimetric (TG) curves were measured on a STA 409/PC
simultaneous thermal analyzer (Netzsch, Germany) with a heating rate of 10 °C min−1 in
blowing air to measure the drug loading capacities of mesoporous CSH microspheres.
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Fourier transform infrared (FTIR) spectra were recorded on a FTIR spectrometer (FTIR7600, Lambda, Australia). The compositions of CSH/polymer composites were
characterized by XRD (Rigaku D/max 2550 V, Cu Kα radiation, λ = 1.54178 Å).

7.2.5

XANES Measurement

XANES measurements were conducted at the Canadian Light Source (CLS) using the
Soft X-ray Microcharacterization Beamline (SXRMB), which is equipped with a double
crystal monochromator with two sets of interchangeable crystals operating with an
energy range of 1.7 to 10 keV. The InSb (111) crystals were used for the Si K-edge
XANES measurements while the Si (111) crystals were used for the Ca K-edge XANES.
The detection modes are total electron yield (TEY) and X-ray fluorescence yield (FLY)
recorded with a Si drift solid state detector, tracking with surface and bulk sensitivities,
respectively.

7.2.6

FEFF Simulation

FEFF is a computer code based on real space multiple scattering theory - it allows the
mathematical modeling of XANES and EXAFS. The crystal structure of the assynthesized CSH nanosheets was reported to be consistent with the 1.4 nm tobermorite
(Ca5Si6O16(OH)2·8H2O) [21], and have space group symmetry of B11b with a lattice
constant of a = 6.735Å, b = 7.425 Å, c = 27.987Å , γ = 123.25°. The locations of the
atoms in Ca5Si6O16(OH)2 are shown in Table 7-1 [22]. To set up a simulation, the
positions of the atomic clusters above are input into the FEFF software. The positions can
be generated by the crystal parameters, including the space group, unit cell parameters,
and the atomic coordination in the unit cell, etc.
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Table 7-1 Atomic coordinates of tobermorite.
Site
Ca1
Ca2
Ca3
Si1
Si2
Si3
O1
O2
O3
O4
O5
OH6
O7
O8
O9

x
0.737
0.879
0.251
0.750
0.895
0.743
0.752
0.760
0.972
0.518
0.887
0.182
0.759
0.501
0.982

y
z
0.425 0.2852
0.994 0.0019
0.428 0.2147
0.386 0.1752
0.750 0.1041
0.961 0.1751
0.512 0.1248
0.189 0.1542
0.554 0.2070
0.301 0.2065
0.250 -0.0482
0.888 0.1175
0.860 0.1252
0.824 0.2067
0.033 0.2069

7.3 Results and Discussion
7.3.1

Morphologies of CSH Nanosheets, CSH/polymer
Composites and CSH/polymer-IBU

The morphologies of CSH nanosheets, various CSH/polymer composites before and after
IBU loading have been characterized by transmission electron spectroscopy, shown in
Figure 7-1. One can see that the specimens consist of warped nanosheets and these
nanosheets stack together (Figure 7-1(a)). Different polymer incorporations and IBU
loadings (Figure 7-1(b) to (h)) do not alter the morphology of CSH nanosheets
significantly. Hence, we cannot obtain much information on the various polymers and
IBU molecules based on the TEM micrographs.
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Figure 7-1 TEM images of CSH nanosheets and CSH/polymer composites before
and after IBU loading: (a) CSH, (b) CSH-IBU, (c) CSH/PDDA, (d) CSH/PDDA-IBU,
(e) CSH/mPEG-PLGA, (f) CSH/mPEG-PLGA-IBU, (g) CSH/PVA, (h) CSH/PVAIBU.

7.3.2

Studies of Interactions between CSH and Different Block
Polymers

The FTIR spectra of the CSH nanosheets and CSH/polymer composites are shown in
Figure 7-2. For CSH nanosheets, the absorption bands in the range of 900-1100 cm-1 are
the stretching vibration of Si-O bonds; the absorption at around 1630 cm−1 is assigned to
the bending vibration of the adsorbed water, and the broad band at 3000-3700 cm-1 is due
to stretching vibration of O-H groups in water or hydroxyls. After different polymers
adsorption, there are no significant FTIR changes except the more noticeable absorptions
at around 2800-2900 cm-1, which are due to C-H stretching from polymer molecules [23,
24]. From the above results, we cannot get much information of different polymers from
FTIR spectra due to the low amount of polymer incorporation.
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Figure 7-2 FTIR spectra of CSH nanosheets, and different CSH/polymer composites.
XRD data of CSH nanosheets and their polymer composites were obtained, as shown in
Figure 7-3. The phase of CSH nanosheets is consistent with that of the 1.4 nm
tobermorite structure (Ca5Si6O16(OH)2·8H2O JCPDS: 29-0331), which was reported in
previous study [21]. Upon composites formation, there are no significant changes for
CSH/PDDA (red) composite; however, for CSH/mPEG-PLGA (navy) and CSH/PVA
(dark cyan) composites, there are new patterns at around 18-19°. Matsuyama et al. [25]
reported that these new patterns can be ascribed to the precipitated polymers themselves.
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Figure 7-3 XRD patterns of CSH nanosheets and different CSH/polymer composites.
In order to confirm and extensively study the interaction between CSH nanosheets and
different polymers, Figure 7-4 shows the Ca K-edge XANES spectra of CSH nanosheets
and their polymers composites. The detection modes are total electron yield (TEY) and
X-ray fluorescence yield (FLY), tracking surface and bulk sensitivity, respectively.
Compare the TEY with the FLY spectra, there are no detectable differences between
them, indicating that the specimens are homogeneous before and after different polymer
composites formation and suffers little thickness effect. Herein we will use TEY XANES
for the following discussion.
There are several discernible XANES features, labelled from “a” to “d”. The pre-edge
peak (feature “a”) can be ascribed to Ca 1s to 3d transition; the shoulder “b” is assigned
to the 1s to 4s transition. Although both of them are formally dipole forbidden, they can
be still observed because of the hybridization of Ca with ligand states of np-character,
leading to the departure from perfect Ca crystal symmetry. The most intense peak
(feature “c”) is due to Ca 1s to 4p dipole transition. The shoulder after the main

154

resonance (feature “d”) is mainly from multiple scattering processes, which is very
sensitive to the immediate surroundings of Ca [26-28].

Figure 7-4 (a) Ca K-edge XANES total electron yield (TEY) and (b) fluorescence
yield (FLY) spectra of CSH/polymer composites and their first derivative spectra (c)
and (d), respectively (dashed arrows in (c) and (d) indicate the changes of CSH/PVA
composites compared with CSH nanosheets).
Compared with the FTIR results, XANES spectra are more sensitive to the structure
changes after the formation of CSH/polymer composites even though the amounts of
polymers incorporations are relative low. Although the spectra of CSH/PDDA (red
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profile) and CSH/mPEG-PLGA (navy) are very similar to that of CSH nanosheets
(black), after close examination of the spectra of CSH/PVA (dark cyan), two subtle
though clearly noticeable changes are observed: one is at the edge jump region (labelled
“b”, 4040 - 4045 eV), which becomes more apparent in the first derivative of the
spectrum (Figure 7-4(c) and (d)), indicated by the dashed arrows; the other is the change
of feature “d”, which can be also observed in the derivative spectrum of CSH/PVA
between 4055 - 4060 eV. Both of these changes can be detected both in TEY and FLY
spectra. Matsuyama et al. [29, 30] found out that the more compact nature of the PVA
chain (~0.45 nm) provided the possibility of intercalating into the structure of CSH (in
this study, CSH has the structure of 1.4 nm (interlayer spacing) tobermorite, Figure 7-5).
The 1.4 nm tobermorite is formed by central Ca-O sheets, connected on both sides to
silicate chains. The space between two layers contains additional calcium cations and
water molecules [22]. As a result, these changes at the Ca K-edge can be ascribed to the
insertion of PVA molecules into the interlayer of CSH, changing the Ca local ordering
(changes of feature “b”) and then alters the multiple scattering pathways (change of
feature “d”). On the contrary, the reason why mPEG-PLGA and PDDA cannot intercalate
into CSH structure may be due to the steric effects or larger chain diameter, and
moreover for PDDA polymer, the cationic N+ ions interact with Ca ions repulsively and
cannot further change the Ca local structure.
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Figure 7-5 Crystal structure of 1.4 nm tobermorite (green, red and beige spheres
stand for Ca, O and Si atoms, respectively; α=900, β=900, and γ=123.250).
Hence mPEG-PLGA and PDDA can only adsorb on the surface of CSH nanosheets,
resulting in the change of the local structure of tetrahedral silicate significantly, which are
shown in Figure 7-6.
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Figure 7-6 (a) Si K-edge XANES total electron yield (TEY) and (b) fluorescence
yield (FLY) spectra of CSH/polymer composites.
At the Si K-edge, for the CSH nanosheets, there is only one peak (“a”, black), which is
ascribed to the Si 1s to 3p transition in a Si-O tetrahedral environment [31, 32]. For all of
the CSH/polymer composites spectra (red, navy, and dark cyan curves), it is interesting to
note that a new feature “b” emerged at a lower energy of the main resonance in TEY
spectra only (Figure 7-6(a)), while their FLY spectra are very similar (Figure 7-6(b)).
This new feature is due to the adsorption of different polymers on the surface of the CSH
nanosheets, inducing the distortion of silicate tetrahedra on the surface, which we have
explained in previous chapters [33, 34]. Since PVA should be intercalated into interlayers
of CSH structure based on the results from the Ca K-edge XANES, there is only subtle
change at its Si K-edge XANES, indicating PVA molecules only change the local
structure of Ca when they are intercalated into the structure of CSH.
Based on the results of the Ca and Si K-edge XANES, we propose the following
interactions between CSH and different polymer molecules, as shown in Figure 7-7. All
of the PDDA, mPEG-PLGA and PVA molecules may distort silicate tetrahedra by the
adsorption on the surface or the defects of CSH nanosheets; only PVA can intercalate
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into the interlayers of CSH structure and changes the Ca local structures because of the
compact nature of PVA chains.

Figure 7-7 Schematic illustration of the interactions between CSH and different
polymers (navy triangle, orange rectangle, green trapezoid stand for PVA, mPEGPLGA and PDDA, respectively; and green, beige and red dots represent calcium,
silicon and oxygen atoms, respectively).

7.3.3

Studies of Interactions between CSH/polymer Composites
and IBU Molecules

Figure 7-8 shows the Ca K-edge XANES spectra of CSH nanosheets and their polymer
composites before and after IBU loading. Similar to the situation before IBU loading,
there are no detectable differences between TEY and FLY of CSH/polymer composites
with IBU loading. However, compared with the spectra before IBU loading, there are
several distinct changes; especially prominent at the features “b” and “d” in the first
derivative spectra (Figure 7-8(c) and (d)). In the case of CSH nanosheets, CSH/mPEGPLGA and CSH/PDDA composites, before IBU loading, there are only two peaks
between 4040-4050 eV in the derivative spectra of feature “b”, but three peaks appear
after the drug is loaded (both in TEY and FLY spectra); moreover, the shoulder features
“d” smear out in all the spectra after IBU loading. These changes have been extensively
studied as presented in Chapter 3 and 5 [35], which are due to the interactions between
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Ca-OH groups and carboxylic acid groups of IBU molecules. What is more interesting is
the observation that the spectra changes after IBU loading into CSH/PVA composites: the
spectrum (dark cyan) after IBU loading is different from all the other three spectra. This
may be due to the combined effects of IBU, PVA molecules to the local structure of Ca
since PVA has been intercalated into the structure of CSH already (Scheme 7-2).

Scheme 7-2 Interactions between CSH, IBU and PVA on the local structure of Ca in
the interlayer of CSH.
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Figure 7-8 Comparisons of (a) Ca K-edge XANES total electron yield (TEY) and (b)
fluorescence yield (FLY) spectra of CSH/polymer composites before and after IBU
loading and their first derivative spectra (c) and (d), respectively.
The effect of IBU loading on the silicate environment has been studied via the Si K-edge
XANES spectra, as shown in Figure 7-9. After IBU loading, feature “b” can only
observed in the TEY of IBU loading samples, which can be ascribed to the combined
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interactions between different polymers, IBU molecules and silanol groups (-Si-OH),
especially for the CSH/mPEG-PLGA-IBU, which has a more intense peak at around
1843 eV (scheme 7-3).

Scheme 7-3 Interactions between CSH, IBU and polymers on the local structure of
silicate on the surface.
Additionally, the IBU loading changed the main resonance “a” as well, both in the TEY
and FY spectra: the main resonance became sharper and shifted to higher energy by 0.2
eV. In chapter 5, we have illustrated that the electrostatic interaction is stronger between
Ca and IBU (due to the activity of Ca-OH, Si-OH to carboxylic acid) than that between
silanol groups and IBU, making original silicate environment a more “isolated”
tetrahedral environment, hence the width of the main resonances at the Si K-edge TEY
and FY became narrower and shifted.
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Figure 7-9 Comparisons of (a) Si K-edge XANES total electron yield (TEY) and (b)
fluorescence yield (FLY) spectra of CSH/polymer composites after IBU loading.
The FTIR spectra of the CSH nanosheets and CSH/polymer composites before and after
the IBU loading are shown in Figure 7-10 to support the XANES analysis. The more
prominent C–H stretching (~ 2800-3000 cm-1), and the appearance of C=O (~ 1560 cm-1)
stretching vibration peaks indicate that IBU has been loaded on the nanosheets and
composites. Nevertheless C=O stretching vibrations are normally located around 1700
cm-1 [23], the red shift of C=O stretching vibration indicates the interactions between the
CSH/polymer composites and the –COOH groups of IBU drug molecules. Besides, the
blue shift of Si–O stretching vibration from 975 cm-1 to 1083 cm−1 also supports this
IBU-silanol groups interaction. The formation of –Si–O–C can increase the polarity of
the Si–O group while reduce the polarity of the C=O group, which results in the blue and
red shifts in the FTIR spectra mentioned above.
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Figure 7-10 Comparisons of FTIR spectra of CSH nanosheets, CSH/polymer
composites before and after IBU drug loading.

7.3.4

Effects of Different Polymer Incorporations on Drug Loading
Capacities and Drug Release Kinetics

After we have demonstrated that the incorporations of different polymers change the
structures of CSH by the analysis of XANES, especially that of the CSH/PVA
composites, it would be necessary to investigate whether or not these interactions may
influence the drug loading capacities (DLCs) and drug release kinetics. Hence, IBU
loading capacities results into different CSH/polymer composites are shown in Figure 711. Compared with the CSH nanosheets alone, all the DLCs of IBU decrease to some
extent after the formation of CSH/polymer composites. This is due to the interactions
between different polymers and CSH nanosheets: parts of the active sites (Ca-OH and SiOH groups) interact with different polymers molecules, leading to the reduction of the
number of active sites for the IBU molecules’ attachment. It should be noted that the IBU
DLCs of CSH/mPEG-PLGA decrease significantly compared with that of CSH
nanosheets. One reason is due to the interactions of CSH and polymers mentioned above,
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the other is the steric and entropic effects, which is one of the key factors that prevents
the IBU molecules’ attachment on the surface of CSH composites.

Figure 7-11 Drug loading capacities (DLCs) of different CSH/polymer composites
(the DLC of CSH nanosheets for comparison).
Figure 7-12 shows the IBU drug release profiles of the IBU-CSH/polymer composites
drug delivery systems in the PBS medium. In Chapter 6, it is shown that the CSH drug
carriers alone do not provide good ability of controlled drug release: there was a burst
drug release effect at the early stage; about 97-98 % of loaded IBU were released in the
first several hours [36], and so are the situations of CSH/PDDA and CSH/mPEG-PLGA
in this study. However, compared with the other two composites, the CSH/PVA-IBU
system shows a relative controlled drug release kinetics, which is largely due to the
intercalation of PVA into the CSH structures, and the combined effects of PVA and IBU
on the structure changes of Ca ions which slowed down the IBU release from the
CSH/PVA composite.
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Figure 7-12 Drug release profiles of different CSH/polymer composites.

7.4 Conclusions
In this chapter, we have shown the structural changes of CSH nanosheets upon the
formation of different polymers composites and the incorporations of IBU molecules by
XANES spectra analysis as summarized below.


PVA molecules can intercalate into to the interlayers of CSH structures and as a
result modify the local structure of interlayer Ca ions and silicate tetrahedra on the
surface; while mPEG-PLGA and PDDA can only adsorb on the surface of CSH
nanosheets leading to the distortion the silicate tetrahedra chains on the surface
because of steric effects.



The IBU loading on these composites further changes the local structure of Ca
and silicate simultaneously by the interactions between the carboxylic acid groups
of IBU and the Ca-OH and Si-OH groups of CSH, which has been extensively
studied in previous chapters already.
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However, the CSH/polymer composites do not enhance the drug loading
capacities of IBU because the active sites for drug molecules’ attachment have
been reduced by the interaction CSH with polymers.



Compared with the other two composite systems, the CSH/PVA composite has a
relatively better controlled drug release profile (delayed release). In our opinions,
this may be due to the PVA intercalation into CSH structures and has a combined
effect with IBU on the structure of interlayer Ca ions after drug loading.

Finally, we have demonstrated that XANES is a sensitive tool to track these effects from
different elemental point of view, and opens up future possibilities for the study of drug
delivery and drug release of bioceramics and their composites.
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Chapter 8

8

Summary, Conclusions, and Future Work

8.1 Summary and Conclusions
In this thesis, the interactions of drug carriers and drug molecules, which play crucial
roles in the determinations of drug loading capacities and drug release kinetics have been
explored. Hence, the focus of this thesis has been on the investigation of the interaction
between calcium silicate hydrate (CSH) and different drug molecules by X-ray
absorption near edge structure (XANES) and scanning transmission X-ray microscopy
(STXM) to understand the local structure change after drug molecules incorporations. It
is also demonstrated that XANES and STXM are so powerful tools with element and
chemical site specificity that they should be widely applied in structural and mechanisms
studies of various biomaterials in the drug delivery fields in the future.
In chapter 3, Ca and Si K-edge XANES studies of CSH with different morphologies
before and after ibuprofen (IBU) loading were presented. It is found that there are
significant interactions of the drug molecules with the carriers from XANES spectra,
accompanied by the local ordering of the system. First, calcium ions interact with
carboxyl groups, generating calcium acetate like compounds. Second, besides hydrogen
bonding between silicates and drug molecules, the most amazing observation is the
strong interaction between silicates and carboxylic groups, forming Si-O-C bonds via
esterification-like reaction. Moreover, drug loading leads to better ordering of silicates
locally. Third, we have demonstrated that the morphology and the presence of hydrates of
drug carriers may influence the drug loading capacities. The CSH drug delivery systems
exhibit high drug loading capacities and excellent sustained drug release behaviors,
which can be potentially applied in various biomedical fields.
In chapter 4, CSH microspheres formed by the self-assembly of nanosheets were
prepared according to a sonochemical method reported previously. The chemical imaging
(with thickness distribution) and interactions between individual CSH microsphere and
IBU on an individual microsphere were studied by STXM at the C and Si K-edges. The
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results suggest that IBU interacts with both Ca-OH and Si-OH groups via its carboxylic
acid functional group; this observation confirms previous analysis that based on a large
collection of many individual CSH nanostructures in the drug delivery system in chapter
3. We find that the drug loading process has no diverse effect on the integrity of IBU
molecules. Moreover, it is of great interest and significance that one can obtain the drug
loading distribution in an individual mesoporous CSH microsphere; IBU molecules are
loaded homogenously into CSH drug carriers.
In chapter 5, the comparative studies of interactions between different functional groups
of ibuprofen, alendronate sodium and gentamicin sulfate, and mesoporous spheres of
CSH were performed by XANES and FTIR spectroscopy in order to establish the
relationship between carrier-drug interactions and drug loading capacities. MS-CSH
provides active linkage sites for acidic functional groups of drug molecules by
electrostatic interactions; while they are not sensitive to the other groups such as amino
and hydroxyl groups. Hence this result will provide some hints to scientists in drug
delivery and materials fields: the acidic drug molecules can be loaded into CSH easily
with higher DLCs; while further surface modifications of CSH such as with acidic groups
on the surface, may provide further incorporation of basic drug molecules into CSH via
the interactions, and may provide high DLCs and controlled drug release profiles.
Besides, the ratio between Ca2+ ions from the CSH carrier and the –COOH groups from
the IBU drug molecules is one main factor responsible for high IBU drug loading
capacity.
In chapter 6, the mechanisms studies of CSH microspheres biomineralization upon IBU
release in the simulated body fluid (SBF) were elucidated by XANES via linear
combination fittings. At the early stages of drug release, crystalline CSH microspheres
disassemble into amorphous flake-like sheets, some silicate ions undergoes exchange into
the SBF solution while others becomes hydrolyzed into amorphous silica. Both Ca (from
CSH and SBF) and PO43- ions (from SBF) first form amorphous calcium phosphate at
first 2h, then quickly transformed into amorphous hydroxyapatite (HAp), and the finally
products were crystalline HAp after the samples were soaked in the SBF solution for
more than 3h. At the same time, some bicarbonate ions (HCO3-) co-precipitate from SBF,
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generating amorphous CaCO3. Moreover, from STXM data, more P were detected around
the area where more Si were located; indicating the abundant silanol groups and the
following hydrolyzed SiO2 provided preference aggregation sites of HAp.
In chapter 7, CSH/polymer composites were synthesized using a controlled precipitation
reaction between calcium salt and silicate salt, followed by the addition of various
polymer solutions at room temperature. We have shown the structural changes of CSH
nanosheets upon the formation of different polymers composites and the incorporations
of IBU molecules by XANES spectra analysis as summarized below. Polyvinyl alcohol
(PVA) molecules can intercalate into to interlayers of CSH structures and as a result
modify the local structure of interlayer Ca ions and silicate tetrahedra on the surface;
while monomethoxy (polyethyleneglycol)-block-poly(DL-lactide-co-glycolide) (mPEGPLGA) and poly(diallyldimethylammonium chloride) (PDDA) can only adsorb on the
surface of CSH nanosheets by distortion the silicate tetrahedral chains on the surface
because of the steric effects. The IBU loading further changes the local structure of Ca
and silicate simultaneously by the interactions between the carboxylic acid groups of IBU
and the Ca-OH and Si-OH groups of CSH, which has been extensively studied in
previous chapters. However, the CSH/polymer composites do not enhance the drug
loading capacities of IBU because the active sites for drug molecules attachment have
been reduced by the interactions with different polymers. Compared with the other two
composite systems, the CSH/PVA composite has a relatively better controlled drug
release profile. In our opinions, this may be due to the PVA intercalation into CSH
structures and has a combined effect with IBU on the structure of interlayer Ca ions after
drug loading.

8.2 Future Work
Calcium silicate is a new type of bioceramics which has gained considerable attentions in
hard-tissue medical treatment because of its satisfactory osteoblast proliferation and
differentiation. It has been shown in this thesis that XANES and STXM are powerful and
sensitive techniques to help understand the carrier-drug interactions and phase
transformation of drug carriers during drug release by correlation with structural changes
of drug carriers before and after drug loading; or by analysis the drug release in vitro

172

products after several time intervals. These findings provide theoretical foresights and
guidance into further surface modifications or functionalization of calcium silicate
carriers to enhance the drug loading capacities, control the drug release kinetics and open
up new possibilities to apply calcium silicate into various fields in future.
Continuing along the results in chapter 5; calcium silicates are only sensitive to the acidic
functional groups of drug molecules, due to the active sites of Ca-OH and Si-OH groups,
thus calcium silicate modified with polyacids (such as acetic acid) on the surface, which
may provide acidic ends on the surface to further attach drug molecules only possess
basic functional groups will be good candidates for XANES study in the next step. It
would be interesting to investigate the structural changes of calcium silicate after surface
modifications and monitor the interactions between basic drug molecules and drug
carriers, which may increase the drug loading capacities of basic drugs and control the
drug release kinetics to some extent.
For the work presented in chapter 7, and that we have successfully mapped the IBU
distribution in individual CSH microsphere in chapter 4, it would be significant to track
the polymers and IBU distributions in the CSH/polymer composites by the analysis the
STXM images and comparison the polymers and IBU spectra at the C K-edge,
respectively.
Europium (Eu) is known as the phosphors because of its intra orbital electronic transition,
which can be applied into biological imaging. What is more important is that it is
functional mimics of Ca ions and can affect the bone remodelling cycle [1]. As a result,
there is an increasing interest in Eu3+ doped HAp and CSH as drug carriers because of the
multi-functionalities [2, 3]. X-ray excited optical luminescence (XEOL) which is an Xray photon-in, optical photon-out technique is more powerful than conventional methods
for studying the optical properties of light emitting materials, because it allows more
pathways for optical decay and elemental specific [4]. Hence, on the basis of XANES
studies, it would be interesting to investigate the structural changes after Eu doping, and
compare the optical properties of drug carriers before and after drug loading using
XEOL.
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Industrial activities generate large quantities of heavy metal bearing wastes every year,
and most of them are toxic, mutagenic, and carcinogenic. Cement is found and is used for
stabilization and solidification of waste materials containing heavy metals [5, 6].
However, the mechanisms of fixation of heavy metals are not completely clear, and
EXAFS has been investigated successfully in the study the Zn sorption mechanism into
CSH [7]. So it would be significant to systematically study the adsorption mechanisms of
different heavy metal ions (such as Ni2+, Cr3+, Cu2+, etc.) into calcium silicate by
XANES, EXAFS, FEFF simulation and linear combination fitting. This study is maybe
going to elucidate some key factors to be considered that will influence the ions
adsorptions, such as atomic diameter, ionic charge, etc.
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